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CHAPTER I 
INTRODUCTION 
Fibroblast to Myofibroblast: A Target Transition for Treating Tissue Fibrosis  
 Fibrosis is defined by excess deposition of extra-cellular matrix (ECM) for which the 
most commonly, identified components are collagen and fibronectin. This progressive injury 
often results in organ failure and death, targeting nearly any tissue in the body. Although specific 
diseases such as scleroderma (SSc), idiopathic pulmonary fibrosis (IPF) and Crohn’s disease are 
relatively rare, when combined with the detrimental contribution of fibrosis in renal, liver, and 
cardiac disease, fibrotic diseases account for 45% of all deaths in the United States (1).   Many of 
these diseases are categorized as autoimmune diseases and are a manifestation of both 
environmental and genetic triggers (2). Although there are many cell types that contribute to 
pathological fibrosis including invading immune cells, damaged epithelial layers, and 
dysfunctional endothelium, local tissue myofibroblasts are the recognized cellular conductors of 
fibrosis. This activated form of a fibroblast is induced by local conditions including mechanical 
stress, growth factors, adhesion proteins and cytokines. These highly contractile cells classically 
express alpha smooth muscle actin (α-SMA) and display increased migration and proliferation. 
During normal physiological events, fibroblasts become activated into myofibroblasts to promote 
wound healing; after epithelialization has occurred they are lost through apoptosis. In the case of 
scleroderma and IPF however, this specialized cell type has become resistant to apoptosis and 
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continues to stimulate fibrogenesis, even in the absence of an identifiable injury (3,4). Over the 
past decades, specific receptor systems which combinatorially induce myofibroblast transition 
have been identified (1). These include lysophosphatidic acid (LPA), endothelin 1 (ET-1), 
connective tissue growth factor (CTGF), transforming growth factor beta (TGFβ), and others. 
However only more recently has a downstream genetic program that regulates and maintains this 
stimulation been defined.  
 Rho GTPases are a sub-family of small GTP-binding proteins within the Ras super-
family, which modulate the actin cytoskeleton. The best-studied members within this subfamily 
are Rac, Cdc42, and RhoA/C. Although each of these affect the cytoskeleton, their specific 
control of regions and cytoskeletal sub-structures classifies their biological role. Rac GTPases 
coordinate actin changes at the leading edge-projection called the lamellipodium. Further 
projections, which extend beyond the lamellipodia, called filopodia, are organized by Cdc42 (5). 
RhoA and RhoC are homologous proteins which regulate highly ordered actin filaments called 
stress fibers (6). Although these two proteins can display subtle differences in biological activity, 
they share similar characteristics. For the work presented here, unless otherwise specified “Rho” 
refers to both RhoA and RhoC.  These small GTPases are often referred to as “molecular 
switches” where their activation is regulated through Rho guanine nucleotide exchange factors 
(GEFs) which directly bind Rho proteins allowing for exchange of GDP for GTP (7). In the 
GTP-bound, active state they are able to interact with downstream effector proteins. Two main 
effector proteins for Rho signaling are Rho-associated, coiled-coil containing protein kinase 
(ROCK) (8,9) and mouse diaphanous-related formin-1 (mDia1) (10). Mechanistically, mDia1 
induces nucleation of F-actin filaments while ROCK phosphorylation modulates F-actin 
3 
 
stabilization though multiple downstream targets including myosin light chain phosphatase 
(MYPT1).  
 Recent analyses of the Rho GTPase signaling cascade have appreciated changes in gene 
expression induced by Rho activity and the serum response factor (SRF) transcription factor. A 
key regulatory mechanism of SRF-mediated gene transcription includes the myocardin related 
transcription co-factors (MRTFA/B) which are regulated by Rho. The N-terminal region of 
MRTFs contains a unique nuclear localization sequence (NLS) which is enveloped by G-actin 
binding motifs, RPxxxEL (RPEL) (11,12). When there is a surplus of G-actin monomers within 
the cytoplasm, the RPEL motifs bind to MRTF sequestering it away from the nucleus. Rho 
activation results in F-actin stress fiber formation, reducing the abundance of G-actin and 
exposing the nuclear localization sequence of MRTF. Trafficking MRTF into the nucleus is 
regulated through direct interaction with importin α/β nuclear import mechanisms (13).   Nuclear 
accumulation of MRTF allows for interaction with SRF and induction of gene expression. 
Importantly, multiple target genes for MRTF/SRF are known drivers of fibrosis (14-18). 
Additionally, SRF-mediated gene transcription has been shown to be essential for myofibroblast 
differentiation (Fig.1-1) (19-21). As the identity of additional microenvironment triggers that 
activate myofibroblasts continues to increase, it raises the question as to which receptor future 
therapies should attempt to target.  
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Figure. 1-1. The fibroblast to myofibroblast transition requires MRTF/SRF gene 
transcription. 
Alpha- smooth muscle actin expressing myofibroblasts are responsible for the excess deposition 
of extracellular matrix components observed in pathological fibrosis. Most notably, collagen and 
fibronectin play important roles in the contractile and fibrous tissue. A variety of 
microenvironment conditions including growth factors, cytokines, mechanical stress and 
adhesion proteins combine to propagate the stimulatory response into MRTF/SRF regulated gene 
transcription and transition into a myofibroblast state. (Reproduced with permission from The 
American Journal of Physiology- Cell Physiology, for full citation see (22)) 
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Profibrotic Signaling Pathways Converge onto Rho GTPases  
 In the past several decades, the specific microenvironment triggers, which stimulate 
fibroblast to myofibroblast transformation, have been partly resolved. These vary from pro-
inflammatory cytokines such as transforming growth factor beta (TGFβ), to G-protein coupled 
receptor (GPCR) ligands like LPA, to components of the extracellular matrix such as CTGF or 
even the mechanical rigidity of the surrounding tissue itself (22-26). There is strong preclinical 
evidence suggesting that many of these pathways may provide opportunities for novel 
therapeutics. Less promising however, several clinical trials that target these individual pathways 
failed due to minimal efficacy. The focus here will be on how these multiple signaling systems 
appear to converge onto Rho GTPase and MRTF (Fig. 1-2). This evidence supports our overall 
approach to target downstream of the receptor, at the merging step in these varied pathways.  
Inflammatory Cytokine TGFβ  
 In fibrotic disorders like scleroderma and IPF, multiple inflammatory cytokines are 
released into the affected tissue by invading immune cells, compromised epithelial and 
endothelial cells, or stimulated myofibroblasts (27-29). Transforming growth factor β (TGFβ) is 
the central profibrogenic cytokine that is an indispensible player in connective tissue homeostasis 
and is considered the “master cytokine” in fibrosis (30). The TGFβ superfamily comprises 
TGFβ1, 2, and 3 which are synthesized by a wide variety of cell types.  Among them TGFβ1 is 
the most abundant and is the prototype of this family. TGFβ signaling occurs when TGFβ 
receptor II, which is constitutively active, trans-phosphorylates and forms a complex with the 
TGFβ-bound TGFβ receptor I.  
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Figure. 1-2. Rho GTPase signaling pathway represent a convergence point for targeting 
fibrosis. 
Many current drugs being developed for fibrotic diseases are targeting specific receptors known 
to be involved stimulating fibroblasts into myofibroblasts. Interestingly many of these specific 
receptor systems converge onto Rho small GTPase signaling. GTP bound active Rho can interact 
with downstream effector proteins, most notibly ROCK kinase and mDia1 which together 
initiate and stabilize actin stress fibers. This increase in F-actin and resulting decrease in G-actin 
monomers frees MRTF to translocate into the nucleus where it cooperates with SRF to induce 
gene transcription. Many MRTF/SRF target genes are known drivers of fibrosis including CTGF, 
α-SMA, and collagen; together this activation of gene transcription induces and maintains the 
activation of fibroblasts to myofibroblasts. (Reproduced with permission from The American 
Journal of Physiology- Cell Physiology, for full citation see (22)) 
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Activated TGFβ receptor phosphorylates serine residues of cytoplasmic R-SMAD, a complex of 
SMAD2 and SMAD3. The two heterodimerize and bind to the co-SMAD, SMAD4, and the 
whole complex translocates across the nuclear membrane to interact with SMAD binding 
elements, recruiting co-activators, co-repressors, or transcription factors to modulate gene 
expression (29).  
 The role of TGFβ in fibrogenesis was demonstrated by Schultz et al  (31) who showed 
that angiotensin II induced cardiac fibrosis in wild type mice but not in TGFβ1 null animals. 
Similar results were obtained in SMAD3 knockout mice, which were protected from bleomycin-
induced skin and lung fibrosis and dimetheylnitrosamine-induced liver fibrosis (32-34). In 
addition, SMAD4 deficient mice were protected from unilateral ureteral obstruction-induced 
renal fibrosis (35). Based on these results, neutralizing antibodies to TGFβ have been evaluated 
in several clinical trials. Despite promising early studies, trials of two anti-TGFβ antibodies 
(CAT-192, TGFβ1; CAT-152, TGFβ2>TGFβ3) did not show clinical improvements in early 
diffuse cutaneous scleroderma (36).  
 Importantly, it has also been observed that TGFβ stimulation leads to Rho activation, 
however, unlike GPCR mechanisms such as LPA and ET-1 which have been well studied, and  
are described below, the pathway leading from TGFβ receptor activation to Rho signaling 
remains mostly unresolved. The formation of stress fibers following GPCR ligand stimulation 
occurs very rapidly while TGFβ induced stress fiber formation is delayed to around 18-24 hours 
following stimulation (37). This raised the possibility of an indirect mechanism such as SMAD 
2/3-dependent transcriptional regulation of other Rho activators (37). Known TGFβ/Smad target 
genes which could induce this activation of Rho include CTGF (38), ET-1 (39), sphingosine 
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kinase-1 (40), or RhoGEFs; NET1 and H1/Lfc (41-43). This gap in knowledge connecting TGFβ 
to Rho signaling becomes the basis for my work in Chapter II of this thesis.  
GPCR Ligands  
LPA and endothelin represent two families of profibrotic GPCR ligands. By acting 
through specific G-protein-coupled receptors, LPA, a phospholipid that is produced by the 
enzyme autotaxin, mediates many diverse cellular responses.  There are currently 6 recognized 
receptors that signal in response to LPA, designated as LPA1-6 (44). Among them, a key role for 
LPA1 has been demonstrated in the development of tissue fibrosis in a variety of organ systems. 
LPA1 acts through three distinct families of G proteins: Gαi/o, Gαq/11, and Gα12/13 (45,46). The 
involvement of LPA signaling in fibrosis has been demonstrated in various animal models of 
skin (47), lung (48), kidney (49), peritoneal fibrosis (50), and liver (51). Bleomycin-induced 
dermal fibrosis, characterized by increased dermal thickness and accumulation of collagen, is 
absent in LPA1 knockout mice (47). In addition, pharmacological antagonism of LPA1 
significantly attenuates bleomycin-induced skin fibrosis in both prevention and therapeutic 
treatment regimens, as well as preventing bleomycin-induced pulmonary fibrosis (52).  Several 
LPA receptor antagonists have entered clinical trials. The LPA1 antagonist AM152 (now termed 
BMS-986020) was safe and well-tolerated in healthy subjects (53) and is now in phase II trials to 
evaluate its safety and efficacy in IPF patients (ClinicalTrials.gov NCT01766817). An LPA1/3 
dual antagonist, SAR100842, is currently in a phase II clinical trial to evaluate safety and 
tolerability in patients with early diffuse cutaneous SSc (ClinicalTrials.gov NCT01651143).  
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There are 3 isoforms of endothelins (ET), ET-1, 2, and 3. Among them, ET-1 is the 
predominant isoform in humans and it acts as a potent vasoconstrictor. It also participates in 
angiogenesis, cell survival, epithelial-to-mesenchymal transition (EMT), and tumor-related 
activities (54). ET-1 is produced by a number of cell types including endothelial cells, epithelial 
cells, smooth muscle cells, fibroblasts, macrophages, and cardiomyocytes, and its expression can 
be induced by various stimuli such as angiotensin II and TGFβ (55). ETs mediate their 
physiological effects by binding to two seven-transmembrane G protein-coupled receptors, ETA 
and ETB. The ETA receptor is ET-1 selective while ETB has equal affinity for all three ET 
isoforms. While ETA appears to be profibrotic, ETB has been shown to be anti-proliferative for 
myofibroblasts (56-58). 
The role of ET-1 in fibrosis has been studied extensively. In healthy lung fibroblasts, ET-
1 is able to induce ECM and α-SMA synthesis as well as contractile activity (59,60). The role of 
ET-1 in promoting fibrogenesis is further demonstrated using transgenic mice with 
overexpression of human ET-1 (61). These animals spontaneously develop progressive 
pulmonary fibrosis and lung inflammation. Blockade of both ETA and ETB receptors suppresses 
TGFβ- or bleomycin-induced fibrosis in vivo (62). ET-1 plays significant roles in the 
pathophysiology of various fibrosis diseases. ET-1 is overexpressed in SSc dermal fibroblasts 
(63) and expression of ET-1 in patient lung tissue correlates with disease severity in diffuse SSc 
patients (64). Enhanced ET-1 expression and binding is observed in lung fibroblasts obtained 
from SSc-interstitial lung disease (ILD) patients and blocking the ET-1 pathway significantly 
reduces α-SMA levels in these cells (60).  
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Concerning LPA and endothelin receptors, the G-protein mediated mechanisms leading 
to activation of Rho have been well mapped. Most notably, receptors which couple to G12/13 
proteins directly activate a family of three RhoGEFs: p115-RhoGEF, PDZ-RhoGEF, and 
leukemia-associated RhoGEF (65). These GEFs then directly interact with members of the Rho 
GTPase family, most notably RhoA and RhoC, inducing exchange of GDP for GTP. This 
facilitates interaction with downstream effector proteins, which are essential for profibrotic 
phenotypes. LPA and endothelin receptors can couple to both G12/13 and Gq/11 (66,67). The 
formation of stress fibers and activation of ROCK following ET-1 stimulation in vitro is likely 
mediated through both G12/13 and Gq/11 family mechanisms (68). Although G12/13 subunits have 
classically been identified to activate Rho through the guanine exchange factors listed above, 
Gq/11 alpha subunits can also directly activate RhoA/C through stimulation of p63 RhoGEF 
(66,69).  
 
Matricellular Protein CTGF 
CTGF, also known as CCN2, is a matricellular protein that belongs to the ECM-
associated signaling CCN family. It is involved in angiogenesis, tissue wound repair, ECM 
regulation, and cellular migration, adhesion, and proliferation (70). Under physiological 
conditions, CTGF is minimally expressed, but in fibrotic conditions, its expression is 
significantly elevated. CTGF functions by binding to various cell surface receptors, including 
integrins (71,72), cell surface heparan sulfate proteoglycans (72), low density lipoprotein 
receptor-related protein/alpha2-macroglobulin receptor (73), and the tyrosine kinase receptor 
TrkA (74). It also binds growth factors and ECM proteins such as vascular endothelial growth 
factor (VEGF) (75), TGFβ/bone morphogenetic proteins (76), and fibronectin (77). CTGF 
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expression is induced by a variety of extracellular stimuli such as TGFβ, PDGF, and ET-1, 
which all utilize a Rho/MRTF mechanism (78). CTGF appears to act as the downstream 
mediator of several of these pro-fibrogenic factors (78). In addition, it reciprocally induces a 
variety of cytokines such as TGFβ and VEGF, forming a positive feedback loop that induces 
more expression of CTGF. It also aids TGFβ in fibrogenesis and helps sustain fibrosis (79).  
Overexpression of CTGF in fibroblasts promotes in vivo fibrosis in multiple organs while 
deletion of it in fibroblasts or smooth muscle cells greatly reduces bleomycin-induced skin 
fibrosis (80,81). In addition, inhibition of CTGF alleviates fibrosis in animal models of cardiac, 
liver, and kidney fibrosis (82-84). A humanized anti-CTGF antibody, FG-3019, has been 
evaluated in several clinical trials for diabetes and kidney disease and is well tolerated in these 
studies. Phase II trials of this approach in IPF (ClinicalTrial.gov NCT01890265) and liver 
fibrosis (ClinicalTrial.gov NCT01217632) are pending. STX-100, a monoclonal antibody 
targeting αvβ6 is also being evaluated in a phase II clinical trial for the treatment of patients with 
IPF (ClinicalTrial.gov NCT01371305). 
CTGF may also function as a positive feedback mechanism in Rho signaling. In addition 
to being a transcriptional target of Rho/MRTF, CTGF has been shown to induce focal adhesion 
complexes and stress fibers through binding of integrin αvβ3 (85).  
 
Cell Substrate Rigidity  
Although traditional ligand-receptor signaling mechanisms have made up a bulk of 
cellular fibrosis research, mechanical signaling between the cell and its structural surroundings 
has also been recently identified as a driver of fibrogenesis. Along with being hyperproliferative 
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relative to normal fibroblasts, myofibroblasts are also highly contractile (86). Along with their 
excess deposition of ECM, myofibroblast contraction leads to the characteristic rigid tissue 
observed in IPF and scleroderma. Interestingly, the resulting stiff matrix environment also feeds 
back onto the myofibroblasts to further promote fibrogenesis (87,88). It has also been recognized 
that alterations in matrix stiffness modulate fibroblast morphology, proliferation, and cytokine 
signaling (89,90). This suggests that cell matrix stiffness could play a significant role in the 
initiation, progression, and stabilization of tissue fibrosis. To a large degree, integrins and focal 
adhesion complexes are the conductors for transmitting a signal from the ECM to the 
intracellular space (88). Integrins are heterodimeric transmembrane glycoproteins which consist 
of non–covalently associated α and β subunits. There are 18 α and 8 β subunits, with a total of 24 
documented heterodimers with distinct specificities for different ECM components. A synthetic, 
small-molecule RGD peptidomimetic antagonist (CWHM 12), that potently inhibits αv-
containing integrins, attenuates CCl4-induced hepatic fibrosis (in both prevention and treatment 
models) (91). In addition to the αv integrins, other integrins also participate in promoting tissue 
fibrosis. Mice bearing specific depletion of fibroblast integrin β1 are resistant to bleomycin-
induced skin fibrosis and have reduced collagen and α-SMA expression (92). Again, Rho 
GTPases are essential for stiff matrix and integrin induced fibrosis (93-95). Similar to TGFβ, 
integrin activation of Rho signaling has been described, but the exact mechanism has not been 
established. It is clear however, that fibronectin and CTGF stimulated integrin signaling results 
in a rapid formation of actin stress fibers and stimulation of the MAP kinase cascade, both of 
which required Rho activity (96). 
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MRTF/SRF Transcription in Cancer Metastasis 
 The classic identity of Rho GTPases revolves around their regulation of the actin 
cytoskeleton and cellular migration (97,98). Although the focus of my work has focused mostly 
on the role of Rho proteins in tissue fibrosis, much of the research on these signaling mediators 
has been related to their involvement in cancer initiation, progression, and especially metastasis 
(99-101). Melanoma is a malignant cancer of melanocytic cells that line the basal layer of the 
epidermis. Although melanoma is less common than other forms of skin cancer, it is much more 
dangerous, resulting in over 50,000 deaths globally each year (102). Melanoma is a prime 
example of how deaths arising from cancer are most commonly dependent on metastasis of the 
primary tumor to an alternative site in the body (103,104). Until very recently, therapeutic 
options for metastatic melanoma were very limited and lacked efficacy (105). Based on the 
prevalence of a common mutation observed in around 50% of human melanomas (BRAF
V600E
), 
targeted therapeutics against mutant BRAF were designed, tested, and approved in 2011 (106). 
As research continues to push the efficacy of and reduce resistance to these targeted therapies, 
even under a best-case scenario these BRAF-targeted drugs will only benefit half of all 
melanoma patients. This presents a clear unmet, clinical need. Another complication with our 
current understanding of the genetic and phenotypic markers of melanoma is the lack of 
definition of determinants of aggressive metastatic melanoma relative to more benign and 
potentially responsive disease. In an effort to identify genes important for melanoma metastasis, 
Hynes et al, (107) compared gene expression patterns from highly metastatic B16F2 mouse 
melanoma cells to those of the parental non-invasive B16 cells. RhoC was found to be 
upregulated and essential for experimental metastasis (107). RhoC was also found to be 
overexpressed in aggressive inflammatory breast cancer (IBC) relative to non-IBC (108,109). To 
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functionally characterize the specific consequences of RhoC overexpression, researchers created 
genetic knockdowns of MRTF and SRF, in the metastatic B16F2 melanoma cells. In the absence 
of MRTF or SRF the metastatic potential of these cells was dramatically reduced in a mouse tail-
vein injection study analyzing lung colonization (109). Interestingly, the in vitro proliferation 
and in vivo primary tumor growth were unaffected in the MRTF knockdowns cells but cellular 
migration and invasion were both reduced. These data suggest that the metastatic potential of 
Rho GTPases is actually driven by MRTF/SRF-regulated gene transcription rather than by a 
direct effect on the actin cytoskeleton itself. In my work here, I investigate activation of this 
pathway as a potential marker of aggressive, metastatic melanomas and also evaluate the efficacy 
of a small-molecule inhibitor of the Rho/MRTF pathway at blocking experimental metastasis.  
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Targeting Rho GTPase/MRTF-Regulated Gene Transcription  
Although individual receptor systems like TGFβ and LPA are important to drive fibrosis, 
treating complex diseases like SSc and IPF may demand a multifaceted approach. Here we 
discuss the gene transcription mechanism (MRTF/SRF) downstream of Rho as an alternative 
target. The convergent role that Rho signaling plays in pathways downstream of LPA, ET-1, and 
TGFβ in fibrosis (Fig. 1-2), suggests that blocking this mechanism may provide greater efficacy. 
Despite the substantial body of work on Rho GTPases in cancer, its importance in fibrosis has 
only recently been recognized (21,110). At first glance, the GTPase itself appears to be the most 
logical target, however, developing potent and selective inhibitors of small GTPases offers 
multiple challenges. The most successful attempts have used virtual screening against the 
structural interface between RhoA and its GEFs. This approach has identified Rhosin and Y16, 
small molecule inhibitors which display high binding affinity and cellular activity in cancer 
models (111,112). These compounds have not yet been tested in fibrosis.  
Instead of targeting the GTPase itself, most pharmaceutical development on this pathway 
has targeted the effector kinase, ROCK. ROCK is a ~160 kDa serine/threonine kinase which is, 
itself regulated by phosphorylation as well as by interaction with Rho GTPase. The two best 
studied inhibitors, fasudil and Y-27632 both bind the ATP site on the kinase enzymatic domain 
effectively inhibiting ROCK activity and both have shown actions in in vitro cardiovascular 
models and in cancer (113). Related to fibrosis, Y-27632 treatment of SSc patient-derived 
fibroblasts inhibits myofibroblast differentiation as well as collagen deposition (110). In vivo 
treatment with fasudil protected mice against experimental lung fibrosis (114). Interestingly, 
fasudil has been used in Japan to treat cerebral vasospasm for nearly twenty years and has a safe 
clinical profile (115). Currently, fasudil is being tested in clinical trials for pulmonary 
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hypertension (116) and Raynaud’s phenomenon (NCT00498615) associated with SSc. While 
ROCK inhibitors may have greater efficacy than blocking individual receptors, the critical gene-
transcription signals downstream of Rho are only partially blocked by Y-27632 (117), perhaps 
because mDia or other mechanisms can bypass ROCK to induce actin stress fibers and nuclear 
translocation of MRTF. 
In our laboratory we identified CCG-1423, the first small molecule inhibitor of 
Rho/MRTF/SRF-regulated gene transcription by use of a SRE-luciferase reporter-based  high-
throughput screen. CCG-1423 was shown to inhibit LPA receptor-stimulated DNA synthesis, 
cell growth, cell survival, and Matrigel invasion in multiple cancer cell lines (117). CCG-1423, 
as well as other structurally related analogs, inhibits Rho/MRTF signaling downstream of 
Rho/ROCK and blocks MRTF nuclear accumulation, possibly through modulation of an 
intranuclear actin-binding protein MICAL-2 (124-127). However, it was recently reported that 
CCG-1423 may directly inhibit MRTF binding to importins (128). In pulmonary fibroblasts, 
CCG-1423 blocked TGF-β induced SRF and α-SMA expression independent of SMAD 
mediated signaling (129). In an in vivo chlorhexidine model of peritoneal fibrosis, CCG-1423 
reduced collagen synthesis and CTGF expression (50). A new analog from this compound series, 
CCG-203971, blocked TGFβ and stiff-matrix-induced expression of profibrotic genes in human 
colonic fibroblasts (130). Taken together these data suggest that further exploration of targeting 
the Rho/MRTF/SRF transcriptional pathway is warranted as a potential new therapy for diseases 
of fibrosis. 
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My Work  
 Based on previous evidence supporting a major role for Rho GTPase mediated 
MRTF/SRF-regulated gene transcription in tissue fibrosis and cancer metastasis, the goal of my 
thesis work was twofold: 1.) Identify mechanisms in scleroderma and metastatic melanoma 
which drive this pathway in these diseases, and 2.) determine efficacy of our current lead small-
molecule inhibitor of this pathway, CCG-203971, in preclinical models on these diseases. This 
work not only assessed the importance of Rho signaling in these diseases but it also identifies 
potential steps in the pathway that could be utilized for novel therapeutic approaches. The 
efficacy studies with CCG-203971, especially the in vivo models, support the continued 
development of these small-molecules.  
 In Chapter II, I focused on answering an imporant biological question identified earlier in 
this section, how does TGFβ activate Rho signaling, actin stress fiber formation, and 
MRTF/SRF-regulated gene transcription? The bulk of this work focused on two very robust and 
simple experimental readouts: F-actin staining assessed through fluorescence microscopy and 
MRTF/SRF luciferase reporter assays. Using NIH-3T3 fibroblasts we observed F-actin stress 
fibers (a hallmark of Rho GTPase activation) and MRTF activation with the luciferase reporter 
within three hours after TGFβ ligand treatment. The F-actin formation was dependent on ROCK 
activity and de novo protein synthesis. With this information, we next analyzed gene expression 
in primary human dermal fibroblasts following TGFβ treatment. Based on the delayed kinetics, 
and sensitivity to ROCK inhibition we identified COL1A1 (Collagen 1α1) and EDN1 
(Endothelin 1) to be TGFβ/SMAD dependent and COL1A2 (Collagen 1α2) and ACTA2 (α-
SMA) to be Rho/MRTF dependent. We also show that endothelin and CTGF both have the 
capacity to stimulate F-actin stress fibers and MRTF activity. Most interestingly, a neutralizing 
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antibody for CTGF and an endothelin receptor type A antagonist can together block TGFβ 
induced stress fibers and MRTF/SRF gene transcription.  
 In Chapter III, we began studies of CCG-203971 in models of scleroderma. Scleroderma 
patient-derived fibroblasts displayed increased expression of MRTF target genes (CTGF, 
ACTA2, and COL1A2) relative to normal healthy donor samples. CCG-203971 was able to 
reduce expression of these genes and selectively blocked proliferation of scleroderma patient 
fibroblasts without effecting fibroblasts from normal donors. CCG-203971 also inhibited TGFβ 
induced protein expression of α-SMA as well as constitutive α-SMA expression observed in the 
scleroderma patient derived fibroblasts. For an in vivo prevention model of scleroderma, we 
injected mice intradermally with bleomycin while treating mice intraperitoneally with CCG-
203971. The compound-treated mice showed decreased dermal layer thickening compared to the 
control group and had reduced total collagen in the treated area. CCG-203971 produced positive 
efficacy in both measured parameters of the model.  
 In Chapter IV, recent evidence for the role of MRTF/SRF in melanoma metastasis, and 
similarities between cancer progression and pathological fibrosis lead us to analyze Rho 
signaling and MRTF/SRF transcription in a panel of five human metastatic melanoma cell lines. 
Using in vitro assays designed to mimic steps in cancer metastasis (colonization, migration, and 
invasion) we identified a clear dichotomy between the cells lines. Three of the lines formed 
colonies, and were highly migratory and invasive in these assays, while the other two were less 
effective. In the aggressive melanomas. RhoC protein expression was dramatically increased and 
MRTF-A was predominantly localized to the nucleus, even in serum-starved cells. These 
melanoma lines also expressed high levels of MRTF target genes; CTGF, MYL9, and CYR61. 
Treatment with CCG-203971 blocked MRTF activity and constitutive nuclear localization in the 
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aggressive melanomas. CCG-203971 also inhibited cellular invasion and migration of the 
aggressive melanomas. To move into an in vivo model of cancer metastasis, we injected 
melanoma cells into the tail-vein of immunocompromised mice and treated with CCG-203971. 
At the end of the study, lung sections were analyzed for the presence of the melanoma cells. The 
compound-treated group displayed a reduction in the total number of metastatic lung colonies, as 
well as decreased size of the colonies. Similar to the efficacy observed in the fibrosis model, 
CCG-203971 dramatically reduced the ability of melanoma cells to colonize the lungs after 
entering systemic circulation.  
 Collaboration was essential for the success of the work presented here. In Chapter III, 
Eliza Tsou, Phillip Campbell, Jeffrey Ruth, and Asif Amin from the University of Michigan, 
Department of Rheumatology, performed the in vivo study shown in Fig. 3-6. In Chapter IV, the 
label-free invasion and migration assays shown in Figs. 4-1 and 4-2 were performed in Dr. Beth 
Lawlor’s lab by Melanie Krook and Merlin Airik from the University of Michigan, Department 
of Pediatrics. Also in Chapter IV, the cell proliferation and effect of CCG-203971 on SRE-
Luciferase shown in Fig. 4-2 and Fig. 4-6, were performed by Sue Wade from our laboratory. I 
performed the remaining experiments at both The University of Michigan Department of 
Pharmacology and Michigan State University Department of Pharmacology and Toxicology.   
  
  
 
 
20 
 
References 
1. Wynn, T. A. (2008) J Pathol 214, 199-210 
2. Alhamad, E. H., Cal, J. G., AlBoukai, A. A., Shaik, S. A., and Omair, M. A. (2014) Clin Respir J  
3. Coward, W. R., Saini, G., and Jenkins, G. (2010) Ther Adv Respir Dis 4, 367-388 
4. Jelaska, A., and Korn, J. H. (2000) Arthritis Rheum 43, 2230-2239 
5. Sit, S. T., and Manser, E. (2011) J Cell Sci 124, 679-683 
6. Vega, F. M., Fruhwirth, G., Ng, T., and Ridley, A. J. (2011) J Cell Biol 193, 655-665 
7. Schwartz, M. (2004) J Cell Sci 117, 5457-5458 
8. Leung, T., Manser, E., Tan, L., and Lim, L. (1995) J Biol Chem 270, 29051-29054 
9. Ishizaki, T., Maekawa, M., Fujisawa, K., Okawa, K., Iwamatsu, A., Fujita, A., Watanabe, N., Saito, 
Y., Kakizuka, A., Morii, N., and Narumiya, S. (1996) Embo J 15, 1885-1893 
10. Tominaga, T., Sahai, E., Chardin, P., McCormick, F., Courtneidge, S. A., and Alberts, A. S. (2000) 
Mol Cell 5, 13-25 
11. Miralles, F., Posern, G., Zaromytidou, A. I., and Treisman, R. (2003) Cell 113, 329-342 
12. Mouilleron, S., Langer, C. A., Guettler, S., McDonald, N. Q., and Treisman, R. (2011) Sci Signal 4, 
ra40 
13. Pawlowski, R., Rajakyla, E. K., Vartiainen, M. K., and Treisman, R. (2010) EMBO J 29, 3448-3458 
14. Mack, C. P., Somlyo, A. V., Hautmann, M., Somlyo, A. P., and Owens, G. K. (2001) J Biol Chem 
276, 341-347 
15. Cen, B., Selvaraj, A., Burgess, R. C., Hitzler, J. K., Ma, Z., Morris, S. W., and Prywes, R. (2003) Mol 
Cell Biol 23, 6597-6608 
16. Luchsinger, L. L., Patenaude, C. A., Smith, B. D., and Layne, M. D. (2011) J Biol Chem 286, 44116-
44125 
17. Selvaraj, A., and Prywes, R. (2004) BMC Mol Biol 5, 13 
18. Hanna, M., Liu, H., Amir, J., Sun, Y., Morris, S. W., Siddiqui, M. A., Lau, L. F., and Chaqour, B. 
(2009) J Biol Chem 284, 23125-23136 
19. Yang, Y., Zhe, X., Phan, S. H., Ullenbruch, M., and Schuger, L. (2003) Am J Respir Cell Mol Biol 29, 
583-590 
20. Chai, J., Norng, M., Tarnawski, A. S., and Chow, J. (2007) Gut 56, 621-630 
21 
 
21. Sandbo, N., Kregel, S., Taurin, S., Bhorade, S., and Dulin, N. O. (2009) Am J Respir Cell Mol Biol 
41, 332-338 
22. Tsou, P. S., Haak, A. J., Khanna, D., and Neubig, R. R. (2014) Am J Physiol Cell Physiol 307, C2-13 
23. Sterclova, M., and Vasakova, M. (2014) World J Clin Cases 2, 668-675 
24. Yan, Z., Kui, Z., and Ping, Z. (2014) Autoimmun Rev 13, 1020-1025 
25. Castelino, F. V., and Varga, J. (2014) Curr Opin Rheumatol 26, 607-614 
26. Duscher, D., Maan, Z. N., Wong, V. W., Rennert, R. C., Januszyk, M., Rodrigues, M., Hu, M., 
Whitmore, A. J., Whittam, A. J., Longaker, M. T., and Gurtner, G. C. (2014) J Biomech 47, 1997-
2005 
27. Fett, N. (2013) Clin Dermatol 31, 432-437 
28. Xu, X., Dai, H., and Wang, C. (2014) Clin Respir J  
29. Lafyatis, R. (2014) Nat Rev Rheumatol 10, 706-719 
30. Zeisberg, M., and Kalluri, R. (2013) American journal of physiology. Cell physiology 304, C216-
225 
31. Schultz Jel, J., Witt, S. A., Glascock, B. J., Nieman, M. L., Reiser, P. J., Nix, S. L., Kimball, T. R., and 
Doetschman, T. (2002) J Clin Invest 109, 787-796 
32. Zhao, J., Shi, W., Wang, Y. L., Chen, H., Bringas, P., Jr., Datto, M. B., Frederick, J. P., Wang, X. F., 
and Warburton, D. (2002) Am J Physiol Lung Cell Mol Physiol 282, L585-593 
33. Lakos, G., Takagawa, S., Chen, S. J., Ferreira, A. M., Han, G., Masuda, K., Wang, X. J., DiPietro, L. 
A., and Varga, J. (2004) Am J Pathol 165, 203-217 
34. Latella, G., Vetuschi, A., Sferra, R., Catitti, V., D'Angelo, A., Zanninelli, G., Flanders, K. C., and 
Gaudio, E. (2009) Liver international : official journal of the International Association for the 
Study of the Liver 29, 997-1009 
35. Meng, X. M., Huang, X. R., Xiao, J., Chung, A. C., Qin, W., Chen, H. Y., and Lan, H. Y. (2012) Kidney 
Int 81, 266-279 
36. Denton, C. P., Merkel, P. A., Furst, D. E., Khanna, D., Emery, P., Hsu, V. M., Silliman, N., Streisand, 
J., Powell, J., Akesson, A., Coppock, J., Hoogen, F., Herrick, A., Mayes, M. D., Veale, D., Haas, J., 
Ledbetter, S., Korn, J. H., Black, C. M., Seibold, J. R., Cat-192 Study, G., and Scleroderma Clinical 
Trials, C. (2007) Arthritis Rheum 56, 323-333 
37. Sandbo, N., Lau, A., Kach, J., Ngam, C., Yau, D., and Dulin, N. O. (2011) Am J Physiol Lung Cell Mol 
Physiol 301, L656-666 
38. Parada, C., Li, J., Iwata, J., Suzuki, A., and Chai, Y. (2013) Mol Cell Biol 33, 3482-3493 
22 
 
39. Rodriguez-Pascual, F., Redondo-Horcajo, M., and Lamas, S. (2003) Circ Res 92, 1288-1295 
40. Yamanaka, M., Shegogue, D., Pei, H. P., Bu, S. Z., Bielawska, A., Bielawski, J., Pettus, B., Hannun, 
Y. A., Obeid, L., and Trojanowska, M. (2004) J Biol Chem 279, 53994-54001 
41. Lee, J., Moon, H. J., Lee, J. M., and Joo, C. K. (2010) J Biol Chem 285, 26618-26627 
42. Shen, X., Li, J. M., Hu, P. P. C., Waddell, D., Zhang, J., and Wang, X. F. (2001) J Biol Chem 276, 
15362-15368 
43. Tsapara, A., Luthert, P., Greenwood, J., Hill, C. S., Matter, K., and Balda, M. S. (2010) Mol Biol Cell 
21, 860-870 
44. Budd, D. C., and Qian, Y. (2013) Future Med Chem 5, 1935-1952 
45. Fukushima, N., Kimura, Y., and Chun, J. (1998) Proc Natl Acad Sci U S A 95, 6151-6156 
46. Contos, J. J., Ishii, I., and Chun, J. (2000) Molecular pharmacology 58, 1188-1196 
47. Castelino, F. V., Seiders, J., Bain, G., Brooks, S. F., King, C. D., Swaney, J. S., Lorrain, D. S., Chun, J., 
Luster, A. D., and Tager, A. M. (2011) Arthritis Rheum 63, 1405-1415 
48. Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., 
Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., and 
Luster, A. D. (2008) Nature medicine 14, 45-54 
49. Pradere, J. P., Klein, J., Gres, S., Guigne, C., Neau, E., Valet, P., Calise, D., Chun, J., Bascands, J. L., 
Saulnier-Blache, J. S., and Schanstra, J. P. (2007) J Am Soc Nephrol 18, 3110-3118 
50. Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., and Tager, A. M. (2013) FASEB J 27, 
1830-1846 
51. Watanabe, N., Ikeda, H., Nakamura, K., Ohkawa, R., Kume, Y., Tomiya, T., Tejima, K., Nishikawa, 
T., Arai, M., Yanase, M., Aoki, J., Arai, H., Omata, M., Fujiwara, K., and Yatomi, Y. (2007) Life Sci 
81, 1009-1015 
52. Swaney, J. S., Chapman, C., Correa, L. D., Stebbins, K. J., Bundey, R. A., Prodanovich, P. C., Fagan, 
P., Baccei, C. S., Santini, A. M., Hutchinson, J. H., Seiders, T. J., Parr, T. A., Prasit, P., Evans, J. F., 
and Lorrain, D. S. (2010) Br J Pharmacol 160, 1699-1713 
53. PRNewswire. (2011) http://www.prnewswire.com/news-releases/amira-pharmaceuticals-
announces-completion-of-phase-1-clinical-study-for-am152-a-novel-lpa1-receptor-antagonist-
121087874.html.   
54. Levin, E. R. (1995) N Engl J Med 333, 356-363 
55. Meyers, K. E., and Sethna, C. (2013) Pediatr Nephrol 28, 711-720 
56. Mallat, A., Fouassier, L., Preaux, A. M., Gal, C. S., Raufaste, D., Rosenbaum, J., Dhumeaux, D., 
Jouneaux, C., Mavier, P., and Lotersztajn, S. (1995) J Clin Invest 96, 42-49 
23 
 
57. Hafizi, S., Wharton, J., Chester, A. H., and Yacoub, M. H. (2004) Cell Physiol Biochem 14, 285-292 
58. Mallat, A., Fouassier, L., Preaux, A. M., Mavier, P., and Lotersztajn, S. (1995) J Cardiovasc 
Pharmacol 26 Suppl 3, S132-134 
59. Xu, S. W., Howat, S. L., Renzoni, E. A., Holmes, A., Pearson, J. D., Dashwood, M. R., Bou-Gharios, 
G., Denton, C. P., du Bois, R. M., Black, C. M., Leask, A., and Abraham, D. J. (2004) J Biol Chem 
279, 23098-23103 
60. Shi-Wen, X., Chen, Y., Denton, C. P., Eastwood, M., Renzoni, E. A., Bou-Gharios, G., Pearson, J. D., 
Dashwood, M., du Bois, R. M., Black, C. M., Leask, A., and Abraham, D. J. (2004) Mol Biol Cell 15, 
2707-2719 
61. Hocher, B., Schwarz, A., Fagan, K. A., Thone-Reineke, C., El-Hag, K., Kusserow, H., Elitok, S., 
Bauer, C., Neumayer, H. H., Rodman, D. M., and Theuring, F. (2000) Am J Respir Cell Mol Biol 23, 
19-26 
62. Lagares, D., Garcia-Fernandez, R. A., Jimenez, C. L., Magan-Marchal, N., Busnadiego, O., Lamas, 
S., and Rodriguez-Pascual, F. (2010) Arthritis Rheum 62, 878-889 
63. Kawaguchi, Y., Suzuki, K., Hara, M., Hidaka, T., Ishizuka, T., Kawagoe, M., and Nakamura, H. 
(1994) Ann Rheum Dis 53, 506-510 
64. Yamane, K., Miyauchi, T., Suzuki, N., Yuhara, T., Akama, T., Suzuki, H., and Kashiwagi, H. (1992) J 
Rheumatol 19, 1566-1571 
65. Siehler, S. (2009) Brit J Pharmacol 158, 41-49 
66. Shraga-Levine, Z., and Sokolovsky, M. (2000) Cell Mol Neurobiol 20, 305-317 
67. Yung, Y. C., Stoddard, N. C., and Chun, J. (2014) J Lipid Res 55, 1192-1214 
68. Kawanabe, Y., Okamoto, Y., Nozaki, K., Hashimoto, N., Miwa, S., and Masaki, T. (2002) Mol 
Pharmacol 61, 277-284 
69. Lutz, S., Freichel-Blomquist, A., Yang, Y., Rumenapp, U., Jakobs, K. H., Schmidt, M., and Wieland, 
T. (2005) J Biol Chem 280, 11134-11139 
70. Campanholle, G., Ligresti, G., Gharib, S. A., and Duffield, J. S. (2013) American journal of 
physiology. Cell physiology 304, C591-603 
71. Babic, A. M., Chen, C. C., and Lau, L. F. (1999) Mol Cell Biol 19, 2958-2966 
72. Gao, R., and Brigstock, D. R. (2004) J Biol Chem 279, 8848-8855 
73. Segarini, P. R., Nesbitt, J. E., Li, D., Hays, L. G., Yates, J. R., 3rd, and Carmichael, D. F. (2001) J Biol 
Chem 276, 40659-40667 
74. Wahab, N. A., Weston, B. S., and Mason, R. M. (2005) J Am Soc Nephrol 16, 340-351 
24 
 
75. Hashimoto, G., Inoki, I., Fujii, Y., Aoki, T., Ikeda, E., and Okada, Y. (2002) J Biol Chem 277, 36288-
36295 
76. Abreu, J. G., Ketpura, N. I., Reversade, B., and De Robertis, E. M. (2002) Nature cell biology 4, 
599-604 
77. Hoshijima, M., Hattori, T., Inoue, M., Araki, D., Hanagata, H., Miyauchi, A., and Takigawa, M. 
(2006) FEBS letters 580, 1376-1382 
78. Jun, J. I., and Lau, L. F. (2011) Nat Rev Drug Discov 10, 945-963 
79. Mori, T., Kawara, S., Shinozaki, M., Hayashi, N., Kakinuma, T., Igarashi, A., Takigawa, M., 
Nakanishi, T., and Takehara, K. (1999) Journal of cellular physiology 181, 153-159 
80. Sonnylal, S., Shi-Wen, X., Leoni, P., Naff, K., Van Pelt, C. S., Nakamura, H., Leask, A., Abraham, D., 
Bou-Gharios, G., and de Crombrugghe, B. (2010) Arthritis Rheum 62, 1523-1532 
81. Liu, S., Shi-wen, X., Abraham, D. J., and Leask, A. (2011) Arthritis Rheum 63, 239-246 
82. Lang, C., Sauter, M., Szalay, G., Racchi, G., Grassi, G., Rainaldi, G., Mercatanti, A., Lang, F., 
Kandolf, R., and Klingel, K. (2008) Journal of molecular medicine 86, 49-60 
83. Uchio, K., Graham, M., Dean, N. M., Rosenbaum, J., and Desmouliere, A. (2004) Wound repair 
and regeneration : official publication of the Wound Healing Society [and] the European Tissue 
Repair Society 12, 60-66 
84. Okada, H., Kikuta, T., Kobayashi, T., Inoue, T., Kanno, Y., Takigawa, M., Sugaya, T., Kopp, J. B., 
and Suzuki, H. (2005) J Am Soc Nephrol 16, 133-143 
85. Chen, P. S., Wang, M. Y., Wu, S. N., Su, J. L., Hong, C. C., Chuang, S. E., Chen, M. W., Hua, K. T., 
Wu, Y. L., Cha, S. T., Babu, M. S., Chen, C. N., Lee, P. H., Chang, K. J., and Kuo, M. L. (2007) J Cell 
Sci 120, 2053-2065 
86. Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmouliere, A., Varga, J., De Wever, O., 
Mareel, M., and Gabbiani, G. (2012) Am J Pathol 180, 1340-1355 
87. Liu, F., Mih, J. D., Shea, B. S., Kho, A. T., Sharif, A. S., Tager, A. M., and Tschumperlin, D. J. (2010) 
J Cell Biol 190, 693-706 
88. Wells, R. G. (2008) Hepatology 47, 1394-1400 
89. Arora, P. D., Narani, N., and McCulloch, C. A. (1999) Am J Pathol 154, 871-882 
90. Wang, H. B., Dembo, M., and Wang, Y. L. (2000) Am J Physiol Cell Physiol 279, C1345-1350 
91. Henderson, N. C., Arnold, T. D., Katamura, Y., Giacomini, M. M., Rodriguez, J. D., McCarty, J. H., 
Pellicoro, A., Raschperger, E., Betsholtz, C., Ruminski, P. G., Griggs, D. W., Prinsen, M. J., Maher, 
J. J., Iredale, J. P., Lacy-Hulbert, A., Adams, R. H., and Sheppard, D. (2013) Nature medicine  
25 
 
92. Liu, S., Kapoor, M., Denton, C. P., Abraham, D. J., and Leask, A. (2009) Arthritis Rheum 60, 2817-
2821 
93. Zhou, Y., Huang, X., Hecker, L., Kurundkar, D., Kurundkar, A., Liu, H., Jin, T. H., Desai, L., Bernard, 
K., and Thannickal, V. J. (2013) J Clin Invest 123, 1096-1108 
94. Schwartz, M. A., and Shattil, S. J. (2000) Trends Biochem Sci 25, 388-391 
95. Marinkovic, A., Liu, F., and Tschumperlin, D. J. (2013) Am J Respir Cell Mol Biol 48, 422-430 
96. Renshaw, M. W., Toksoz, D., and Schwartz, M. A. (1996) J Biol Chem 271, 21691-21694 
97. Hanna, S., and El-Sibai, M. (2013) Cell Signal 25, 1955-1961 
98. Murali, A., and Rajalingam, K. (2014) Cell Mol Life Sci 71, 1703-1721 
99. Wilson, K. F., Erickson, J. W., Antonyak, M. A., and Cerione, R. A. (2013) Trends Mol Med 19, 74-
82 
100. Baranwal, S., and Alahari, S. K. (2011) Curr Drug Targets 12, 1194-1201 
101. Li, H., Peyrollier, K., Kilic, G., and Brakebusch, C. (2014) Biofactors 40, 226-235 
102. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010) Int J Cancer 127, 
2893-2917 
103. Azoury, S. C., and Lange, J. R. (2014) Surg Clin North Am 94, 945-962, vii 
104. Chen, Y. Q. (2013) Cancer Metastasis Rev 32, 3-4 
105. Finn, L., Markovic, S. N., and Joseph, R. W. (2012) BMC Med 10, 23 
106. Jang, S., and Atkins, M. B. (2014) Clin Pharmacol Ther 95, 24-31 
107. Clark, E. A., Golub, T. R., Lander, E. S., and Hynes, R. O. (2000) Nature 406, 532-535 
108. van Golen, K. L., Wu, Z. F., Qiao, X. T., Bao, L. W., and Merajver, S. D. (2000) Cancer Res 60, 5832-
5838 
109. van Golen, K. L., Wu, Z. F., Qiao, X. T., Bao, L., and Merajver, S. D. (2000) Neoplasia 2, 418-425 
110. Akhmetshina, A., Dees, C., Pileckyte, M., Szucs, G., Spriewald, B. M., Zwerina, J., Distler, O., 
Schett, G., and Distler, J. H. (2008) Arthritis Rheum 58, 2553-2564 
111. Shang, X., Marchioni, F., Sipes, N., Evelyn, C. R., Jerabek-Willemsen, M., Duhr, S., Seibel, W., 
Wortman, M., and Zheng, Y. (2012) Chem Biol 19, 699-710 
112. Shang, X., Marchioni, F., Evelyn, C. R., Sipes, N., Zhou, X., Seibel, W., Wortman, M., and Zheng, Y. 
(2013) Proc Natl Acad Sci U S A 110, 3155-3160 
26 
 
113. Liao, J. K., Seto, M., and Noma, K. (2007) J Cardiovasc Pharmacol 50, 17-24 
114. Zhou, Y., Huang, X. W., Hecker, L., Kurundkar, D., Kurundkar, A., Liu, H., Jin, T. H., Desai, L., 
Bernard, K., and Thannickal, V. J. (2013) J Clin Invest 123, 1096-1108 
115. Ying, H., Biroc, S. L., Li, W. W., Alicke, B., Xuan, J. A., Pagila, R., Ohashi, Y., Okada, T., Kamata, Y., 
and Dinter, H. (2006) Mol Cancer Ther 5, 2158-2164 
116. Raja, S. G. (2012) Recent Pat Cardiovasc Drug Discov 7, 100-104 
117. Evelyn, C. R., Wade, S. M., Wang, Q., Wu, M., Iniguez-Lluhi, J. A., Merajver, S. D., and Neubig, R. 
R. (2007) Molecular Cancer Therapeutics 6, 2249-2260 
118. Etienne-Manneville, S., and Hall, A. (2002) Nature 420, 629-635 
119. Turner, S. J., Zhuang, S., Zhang, T., Boss, G. R., and Pilz, R. B. (2008) Biochem Pharmacol 75, 405-
413 
120. Brandes, R. P. (2005) Circ Res 96, 927-929 
121. Watts, K. L., Sampson, E. M., Schultz, G. S., and Spiteri, M. A. (2005) Am J Resp Cell Mol 32, 290-
300 
122. Xu, J. F., Washko, G. R., Nakahira, K., Hatabu, H., Patel, A. S., Fernandez, I. E., Nishino, M., 
Okajima, Y., Yamashiro, T., Ross, J. C., Estepar, R. S., Diaz, A. A., Li, H. P., Qu, J. M., Himes, B. E., 
Come, C. E., D'Aco, K., Martinez, F. J., Han, M. K., Lynch, D. A., Crapo, J. D., Morse, D., Ryter, S. 
W., Silverman, E. K., Rosas, I. O., Choi, A. M., and Hunninghake, G. M. (2012) Am J Respir Crit 
Care Med 185, 547-556 
123. Nadrous, H. F., Ryu, J. H., Douglas, W. W., Decker, P. A., and Olson, E. J. (2004) Chest 126, 438-
446 
124. Evelyn, C. R., Bell, J. L., Ryu, J. G., Wade, S. M., Kocab, A., Harzdorf, N. L., Showalter, H. D. H., 
Neubig, R. R., and Larsen, S. D. (2010) Bioorg Med Chem Lett 20, 665-672 
125. Bell, J. L., Haak, A. J., Wade, S. M., Kirchhoff, P. D., Neubig, R. R., and Larsen, S. D. (2013) Bioorg 
Med Chem Lett 23, 3826-3832 
126. Jin, W. Z., Goldfine, A. B., Boes, T., Henry, R. R., Ciaraldi, T. P., Kim, E. Y., Emecan, M., Fitzpatrick, 
C., Sen, A., Shah, A., Mun, E., Vokes, M., Schroeder, J., Tatro, E., Jimenez-Chillaron, J., and Patti, 
M. E. (2011) Journal of Clinical Investigation 121, 918-929 
127. Lundquist, M. R., Storaska, A. J., Liu, T. C., Larsen, S. D., Evans, T., Neubig, R. R., and Jaffrey, S. R. 
(2014) Cell 156, 563-576 
128. Hayashi, K., Watanabe, B., Nakagawa, Y., Minami, S., and Morita, T. (2014) Plos One 9, e89016 
129. Sandbo, N., Kregel, S., and Dulin, N. O. (2009) Am J Resp Crit Care 179 
27 
 
130. Johnson, L. A., Rodansky, E. S., Haak, A. J., Larsen, S. D., Neubig, R. R., and Higgins, P. D. (2014) 
Inflamm Bowel Dis 20, 154-165 
 
29 
 
 
CHAPTER II 
THE ROLE OF CTGF AND ET-1 IN TGF-BETA STIMULATED ACTIN STRESS 
FIBERS AND RHO-KINASE DEPENDENT TRANSCRIPTION OF PROFIBROTIC 
GENES ACTA2 AND COL1A2 
Abstract 
Fibrotic disorders like systemic sclerosis and idiopathic pulmonary fibrosis remain debilitating 
diseases that have only recently been the target for approved therapeutics. Although tissue 
fibrosis is driven by a variety of mediators, the best established is transforming growth factor 
beta (TGFβ). Canonical TGFβ signaling modulates gene expression through activation of the 
SMAD family transcription factors. TGFβ also induces a delayed stimulation of Rho GTPase 
and myocardin-related transcription factor (MRTF) however; the mechanism for this activation 
and the dependence of specific profibrotic genes being expressed by MRTF vs. SMAD has not 
been examined. Here we report an analysis of stress fiber formation, MRTF activation, and gene 
expression following TGFβ stimulation in NIH-3T3 fibroblasts and primary human dermal 
fibroblasts. Specifically, TGFβ stimulates stress fiber formations peaking at 3 hours and 
maintains them out to 24 hours post treatment. Known SMAD target genes COL1A1, and EDN1 
(ET-1) were expressed rapidly following TGFβ, while MRTF target genes COL1A2 and 
ACTA2, were not expressed until 12-18 hours after treatment and were dependent on Rho-kinase 
(ROCK) activity. CTGF, which is a known target for both SMAD and MRTF regulated 
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transcription, was rapidly expressed, and later enhanced at 12-18 hours after TGFβ. To assess 
intermediary signaling on TGFβ activation of the Rho pathway we used a neutralizing antibody 
for CTGF and an ET-1 receptor antagonist, which were able to block TGFβ stimulated stress 
fiber formation and MRTF activity. These data point towards a mechanism were canonical 
TGFβ/SMAD signaling leads to transcription of CTGF and ET-1 that additively stimulate F-
actin stress fibers, and MRTF to promote fibrosis through expression of COLA1A2, ACTA, and 
CTGF.   
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Introduction  
 Pathological tissue fibrosis which occurs in systemic sclerosis (SSc) and idiopathic 
pulmonary fibrosis (IPF) develops into progressive and poorly managed diseases. These 
disorders are characterized by aberrant wound healing, rigid structural irregularities of the 
affective tissue leading to deteriorating organ function, and potential fatality (1-3).  At the 
cellular level, fibrosis is driven in part, by local fibroblasts differentiated into active 
myofibroblasts which display enhanced proliferation and extra-cellular matrix deposition (4,5). 
The myofibroblasts also induce contraction of the matrix substrate that further promotes stiff, 
fibrotic tissue (6,7). Multiple micro-environment factors can influence signaling cascades to 
promote myofibroblast differentiation; however the best established is transforming growth 
factor-beta (TGFβ) (8,9). TGFβ superfamily ligands bind to a type II receptor, (TGFβRII) which 
then phosphorylates and activates a type I receptor (TGFβRI). Once active, TGFβRI 
phosphorylates receptor-regulated SMADs (R-SMADs), (SMAD2/3). To activate gene 
transcription, SMAD2/3 complexes with SMAD4 and accumulates in the nucleus where it 
induces transcription of a variety genes involved in extracellular matrix neogenesis (10). Known 
profibrotic, TGFβ/SMAD target genes include: COL1A1 (collagen type 1 α1), CTGF 
(connective tissue growth factor/CCN2), and EDN1 (endothelin-1) (11-13). Clinically, TGFβ 
expression is elevated in the dermis of patients with SSc (14,15), and in the plasma of IPF 
patients (16). TGFβ also participates in non-canonical signaling through a variety of mechanisms 
(17).  
 Rho family GTPases regulate cytoskeletal organization, cell motility, and gene 
expression through multiple effector proteins (18). As a means to regulate gene expression, Rho-
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GTPase stimulates the formation of F-actin filaments through the Rho kinase (ROCK), thereby 
depleting cellular stores of G-actin. Myocardin-related transcription factors (MRTF) are 
normally sequestered in the cytosol by G-actin but following Rho activation accumulate in the 
nucleus to cooperatively activate gene transcription with the serum response factor (SRF) 
(19,20). Known profibrotic, MRTF/SRF target genes include: COL1A2 (collagen type 1 α2), 
ACTA2 (alpha- smooth muscle actin), and CTGF (21-24). One well-established mechanism for 
Rho GTPase activation and F-actin stress fiber formation is through G protein-coupled receptors 
(GPCRs) which bind to G12/13 subunits to activate one of the RhoGEFs (p115-RhoGEF, PDZ-
RhoGEF, leukemia-associated RhoGEF) which directly binds to and activates RhoA and RhoC 
(25). The kinetics of this pathway are also well established and relatively rapid; following LPA 
ligand addition, fibroblasts form actin stress fibers within 10 minutes (26). TGFβ activation of 
Rho and Rho effector mechanisms has been observed in multiple cell types. In fibroblasts, F-
actin stress fibers are observed following TGFβ treatment, however their formation is delayed 
relative to that seen with GPCR signaling, developing on the scale of hours after TGFβ rather 
than minutes after LPA (27,28). Rapid activation of RhoA by TGFβ (10 minutes) has been 
observed in epithelial cells, but was found to be independent of canonical SMAD signaling (29). 
The delayed activation occurring in fibroblasts however, is dependent on SMAD transcriptional 
activity and de novo protein synthesis, (28)  suggesting that TGFβ/SMAD signaling promotes 
expression of some Rho activating mediator. Also, TGFβ stimulation activates Rho kinase-
dependent MRTF/SRF-regulated gene expression as well as pulmonary myofibroblast 
differentiation (28).  
 Recent evidence suggests that SRF-regulated gene transcription through MRTF is 
essential for the differentiation and stabilization of activated myofibroblasts (30-32), a critical 
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step in tissue fibrosis. Taken together, these results suggest that MRTF/SRF regulated gene 
transcription driven by Rho GTPase induced F-actin dynamics is potentially a key component for 
TGFβ induced fibrosis. There are, however, major gaps in the understanding of TGFβ activation 
of Rho GTPase and MRTF transcription; this includes the kinetics of actin reorganization and 
MRTF-regulated gene transcription following TGFβ treatment of fibroblasts, and potential 
intermediate mediators by which this activation occurs. Enhanced understanding of these factors 
could identify novel therapeutic targets in tissue fibrosis, or promote a combination therapy with 
currently approved therapeutics to target these complex diseases.  
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Materials and Methods  
Patient sample and Animal Use 
Primary human dermal fibroblasts were obtained by two punch biopsies (4 mm) taken from the 
forearm of mixed sex, healthy volunteers. The tissue was digested using enzyme digestion 
solution containing 2.4 units/ml dispase, 650 units/ml type II collagenase, and 10,000 Dornase 
units/ml DNase. Dermal fibroblasts were maintained in DMEM with 10% fetal bovine serum 
(FBS), penicillin, and streptomycin. Cells of passages between 4 and 6 were used. Written 
informed consent was obtained for all subjects and the study was approved by the University of 
Michigan Institutional Review Board. NIH-3T3 cells obtained from ATCC were also maintained 
in 10% FBS containing DMEM, penicillin, and streptomycin. 
F-actin Fluorescence Microscopy  
NIH-3T3 cells (6.0X10
3
) were plated into each well of an 8-well tissue culture treated chamber 
slide (Falcon) and allowed to attach overnight. Medium was changed to DMEM containing 0.5% 
FBS for 24 hours +/- the indicated concentrations and times of TGFβ1 (R&D Systems), 1-
Palmitoyl Lysophosphatidic Acid (Cayman Chemical), recombinant human CTGF (Life 
Technologies), recombinant human endothelin-1 (Sigma-Aldrich), Y-27632 (Sigma-Aldrich), CI 
1020 (Tocris Chemical), and/or CTGF neutralizing antibody (Abcam ab109606). Cells were then 
fixed in 3.7% formaldehyde for 10’ at room temperature (RT) and permeabilized with 0.25% 
Triton X-100 for 10’ at RT. For F-actin staining one unit of Acti-Stain® 488 phalloidin 
(Cytoskeleton Inc.) was added to each cover slip for 30’ at RT. Cells were mounted with Prolong 
Gold® antifade reagent with DAPI (Invitrogen) and imaged on an inverted fluorescence 
microscope (EVOS FL, Life Technologies).  
35 
 
qPCR 
Primary human dermal fibroblasts (1.0X10
5
) were plated into 6-well plates (Falcon #353046) 
and starved for 24 hours in DMEM containing 0.5% FBS with the indicated concentrations and 
times of TGFβ1, LPA, and/or Y-27632. Cells were lysed and RNA was isolated using the 
RNeasy® kit (Qiagen) following the manufacturer’s directions. DNAse-treated RNA was 
quantified using a NanoDrop® spectrophotometer and 1 µg was used as a template for 
synthesizing cDNA utilizing the Taqman® Reverse-Transcription Reagents kit (Invitrogen). 
SYBR green qPCR (SABiosciences) was performed using a Stratagene Mx3000P (Agilent 
Technologies). Ct values were determined and mRNA expression calculated relative to that of 
GAPDH. Fold changes were calculated using ΔΔCt calculation. Primer sequences were: 
GAPDH; 5’ GGAAGGGCTCATGACCACAG. 3’ ACAGTCTTCTGGGTGGCAGTG. CTGF; 
5’ CAGAGTGGAGCGCCTGTT. 3’ CTGCAGGAGGCGTTGTCA. ACTA2; 5’ 
AATGCAGAAGGAGATCACGC. 3’ TCCTGTTTGCTGATCCACATC. COL1A2-hn; 5’ 
CTTGCAGTAACCTTATGCCTAGCA. 3’ CCCATCTAACCTCTCTACCCAGTCT. EDN1; 5’ 
CTTCGTTTTCCTTTGGGTTCAG.  3’ GCTCAGCGCCTAAGACTG. COL1A1-hn; 5’ 
CTTGCAGTAACCTTATGCCTAGCA. 3’  CCAACTCCTTTTCCATCATACTGA. All mRNA 
values were normalized to a control (either normal fibroblasts or a vehicle control) run the same 
day.  
Statistics 
Statistical analysis was performed by ANOVA comparison between groups followed by 
Bonferonni posttest where * p> 0.05, ** P>0.01, and *** P>0.001.  
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Results 
TGFβ stimulates delayed but stabilized F-actin stress fibers.  
 TGFβ has been shown to produce F-actin stress fibers very rapidly (10 minutes) (29), as 
well as in a delayed manner up to and beyond 24 hours (28). To directly assess TGFβ stimulated 
stress fiber formation kinetics, we treated NIH-3T3 fibroblasts with 10ng/mL TGFβ for various 
times up to 24 hours. As a positive control, we treated cells with 10µM LPA for 30 minutes, as 
previously reported LPA induced stress fibers within the first 5-10 minutes, (data not shown). 
TGFβ stimulates actin stress fibers peaking around 3 hours, and interestingly maintains around 
40% positive cells throughout the time course (Fig. 2-1A). To determine if the F-actin 
stimulation at the peak (3 hours) is dependent on the Rho-GTPase pathway, cells were treated 
with 10µM Y-27632 (Rho-kinase inhibitor). Similarly to previous findings, (28) Y-27632 
blocked TGFβ induced stress fibers (Fig. 2-1B). Using cycloheximide (CHX), we assessed the 
requirement of de novo protein synthesis following TGFβ signaling in F-actin stimulation (Fig. 
2-1B). CHX also blocked the presence of TGFβ-stimulated stress fibers at 3 hours. To verify that 
the CHX treatment is not just non-specifically blocking F-actin formation, we stimulated cells 
with LPA in the presence of CHX and found no inhibition of stress fiber formation (Fig. 2-2). 
Together these data further suggest some newly synthesized protein mediator drives Rho 
activation of the actin cytoskeleton following TGFβ signaling.  
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Figure 2-1. TGFβ stimulated F-actin stress fibers are dependent on Rho-kinase and de 
novo protein synthesis. 
A.)  Kinetic profile of TGFβ stimulated F-actin stress fibers. NIH-3T3 fibroblasts were starved in 
0.5% FBS medium +/- 10ng/mL TGFβ for the indicated amount of time (hours). 10µM LPA 
treated for 30 minutes was used for comparison and positive control for stress fibers stimulated 
through established mechanism and kinetics.  
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Figure. 2-1. (continued) Representative images are shown for non-treated control, LPA, and 
TGFβ at 3 hours. F-actin was stained along with DAPI nuclear staining and four images from 
each experiment were examined for cells which displayed F-actin stress fiber formations. Data 
represents the mean (+/- SEM) from three independent experiments. Shown are representative 
images from each condition. Scale bar represents 100µm. B.) TGFβ stimulated stress fibers are 
blocked through Rho-kinase inhibition and cycloheximide (CHX) inhibition of protein synthesis. 
Starved NIH-3T3 cells were treated with 10µM ROCK inhibitor, Y-27632 (24 hours) or 
10µg/mL CHX (3 hours) and stimulated with TGFβ for 3 hours and quantified as above. Data 
represents the mean (+/- SEM) from three independent experiments. Scale bar represents 100µm. 
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Figure 2-2. LPA stimulated stress fibers are independent of de novo protein synthesis. 
LPA stimulated stress fibers are blocked through Rho-kinase inhibition but not cycloheximide 
(CHX) inhibition of protein synthesis. Starved NIH-3T3 cells were treated with 10µM ROCK 
inhibitor, Y-27632 (24 hours) or 10µg/mL CHX (3 hours), stimulated with 10µM LPA for 30 
minutes, and quantified as above. Data represents the mean (+/- SEM) from three independent 
experiments. Scale bar represents 100µm. 
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TGFβ initiates delayed but prolonged activation of MRTF/SRF transcription.  
 To investigate the downstream transcriptional outputs following TGFβ signaling, we used 
a luciferase transcription reporter of SRF that is specific for MRTF/SRF activity (33). Evaluating 
concentration response curves with TGFβ and LPA we focused at 6 and 18 hours after ligand 
addition (Fig. 2-3A). This revealed that at 6 hours TGFβ was unable to produce an appreciable 
signal. In comparison, LPA produced a robust response, peaking at ~8 fold induction relative to 
control (EC50 ~3µM). The opposite was seen at 18 hours after treatment. The LPA signal was 
lost and TGFβ produced a peak response of ~5 fold over control (EC50 ~0.6ng/mL) (Fig. 2-3A). 
This suggests the MRTF/SRF luciferase reporter is relatively dynamic and can be used to 
produce a kinetic profile of TGFβ signaling. Using this reporter, we investigated a time course 
out to 30 hours for MRTF activity following LPA and TGFβ treatment (Fig. 2-3B). LPA 
produces a rapid, but transient activation of MRTF while TGFβ activates a delayed, but stable 
MRTF activation. To show that activation through either ligand is dependent on the Rho 
signaling pathway we pre-treated the cells with the Rho-kinase inhibitor Y-27632 for 24 hours 
then stimulated with 10ng/mL TGFβ (18 hours) or 10µM LPA (6 hours) (Fig. 2-3C). Through 
either regulated transcription mechanism, Y-27632 displayed equal potency and efficacy for 
inhibition of MRTF-activated luciferase expression (IC50~ 3µM). 
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Figure 2-3. TGFβ activates delayed MRTF/SRF regulated transcription. 
A.) Dose-response curves of acute (6 hour) and delated (18 hour) MRTF/SRF regulated 
luciferase reporter assays with LPA and TGFβ. NIH-3T3 fibroblasts were transfected with 
MRTF dependent SRE-Luciferase reporter plasmids then stimulated at either 18 or 6 hours with 
the indicated concentrations of LPA and TGFβ.  
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Figure 2-3. (continued) B.) Kinetic profile of LPA and TGFβ activated MRTF/SRF luciferase 
reporter. As above, NIH-3T3 cells were transfected with SRE-Luc reporter plasmid and treated 
for the indicated number of hours with 10µM LPA or 10ng/mL TGFβ (near maximum response 
concentrations). C.) LPA and TGFβ stimulated MRTF/SRF luciferase are dependent on Rho-
kinase activity. NIH-3T3 cells transfected with the MRTF/SRF luciferase reporter were treated 
for 24 hours with the indicated concentrations of the Rho-kinase inhibitor Y-27632 then 
stimulated with 10µM LPA (6 hours) or 10ng/mL TGFβ (18 hours). Luciferase experiments 
were multiplexed with WST-1 to monitor cellular proliferation/toxicity and data represents the 
mean (+/- SEM) of luciferase luminescence relative to WST-1 absorbance and normalized to the 
untreated control of three (A,C) or two (B) independent experiments.  
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TGFβ initiates rapid SMAD target gene transcription and delayed expression of MRTF target 
genes.   
 To assess the significance of the postponed stress fibers and MRTF activation observed 
in NIH-3T3 cells following TGFβ treatment we assessed transcriptional levels of known SMAD 
and MRTF profibrotic target genes in human primary dermal fibroblasts through a 30-hour time 
course after TGFβ addition (Fig. 2-4). To identify MRTF target genes, we also performed the 30-
hour time course following LPA addition (Fig. 2-4). Previously identified SMAD target genes 
COL1A1 (11), and EDN1 (13), displayed robust (~3 fold) stimulation within the first hour of 
TGFβ treatment and no stimulation following LPA treatment. However, previously identified 
MRTF target genes COL1A2 (21), and ACT2 (23), show enhanced mRNA levels within the first 
hour of LPA stimulation. Consistent with the kinetics that we observed for stress fiber formation 
and MRTF luciferase reporter activation, TGFβ begins stimulating expression of MRTF target 
genes at some point after 6 hours and they continue to rise up to the 30 hour mark (Fig. 2-4). 
CTGF (the gene encoding CCN2 protein), has been shown to be a target for TGFβ/SMAD 
signaling as well as for Rho/MRTF signaling (10, 27). Consistent with these findings we observe 
rapid stimulation of CTGF within the first few hours of TGFβ treatment and further enhancment 
at the later time points, suggesting based on the COL1A2 and ACTA2 TGFβ stimulated profiles, 
that around the 12 hour mark MRTF transcription is activated and driving peak CTGF expression 
(>10 fold at 30 hours). This is further supported by the LPA stimulated CTGF profile which 
promotes 5 fold expression within the first few hours after treatment (Fig. 2-4).  
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Figure 2-4. Kinetic profile of profibrotic gene transcription following TGFβ and LPA 
treatment. 
Primary human dermal fibroblasts obtained from healthy donors (≤ passage 6) were stimulated 
for the indicated amount of time with 10ng/mL TGFβ or 10µM LPA in 0.5% serum starved 
medium. RNA was analyzed by qPCR to determine relative expression levels of profibrotic 
genes COL1A1, EDN1, COL1A2, ACTA2, and CTGF. Based on previous literature and the 
results obtained here these genes categorize into SMAD target genes, MRTF target genes, or 
combined SMAD/MRTF target genes. Data represents the mean (+/- STD) of two independent 
experiments; expression levels were quantified relative to GAPDH and normalized to the 
untreated control. 
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TGFβ stimulation of MRTF target genes is dependent on Rho-kinase activity.  
 To further support our discrimination of the role of MRTF and SMADs in controlling 
genes stimulated by TGFβ, we measured gene expression following 6 and 24 hours of TGFβ and 
6 hours of LPA, with and without 10 µM Y-27632 (Fig. 2-5). As predicted, the expression of 
SMAD target genes COL1A1 and EDN1 is not blocked by ROCK inhibition, however, 
transcription of the MRTF target genes COL1A2 and ACTA2, which are transcribed late (24 
hours) after TGFβ and early (6 hours) with LPA are blocked by ROCK inhibition. Also 
consistent with this model, the early TGFβ stimulation of CTGF with is not affected by Y-27632 
but the later enhancement at 24 hours, as well LPA stimulated transcription, is blocked with the 
Rho-kinase inhibitor Y-27632. 
 
CTGF and ET-1 stimulate stress fiber formation and activate MRTF/SRF  regulated 
transcription.    
 Previous findings, as well as the effect of cycloheximide on stress fibers following TGFβ 
treatment, (Fig. 2-1B), suggest that a target gene product(s) of TGFβ mediates the delayed 
activation of Rho GTPase and stress fiber formations. As shown throughout the experiments 
performed here, LPA potently induces Rho activation and MRTF regulated gene transcription. 
To assess the potential role of LPA in TGFβ stimulated stress fibers, we measured RNA levels of 
ENPP2 (autotaxin or ATX), the gene encoding the enzyme that regulates LPA production (34). 
Following TGFβ treatment, ATX levels decreased in a time depenent maner (Fig. 2-6A). 
Contrary to the expectation if LPA was the mediator of TGFβ induced Rho activation. We also 
found that the LPA receptor1/3 antagonist, Ki16425 reduced the background level of MRTF-
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regulated luciferase reporter in starved fibroblasts even in the absense of ligand. However it did 
not suppress TGFβ induced MRTF activity (Fig. 2-6B). Alternative mediators could be 
endothelin and CTGF. Along with being identified as TGFβ/SMAD target genes, both ET-1 and 
CTGF have been shown to activate the Rho GTPase pathway and stimulate actin stress fibers 
(35-37). Here we show that both CTGF and ET-1 stimulate stress fibers in starved NIH-3T3 
fibroblasts as early as 1 hour after adding ligand, similar to LPA (Fig.2-7A). We also measured 
MRTF activity following addition of CTGF and ET-1 using the SRE-Lucifferase reporter and 
found both treatsments activated MRTF activity (Fig. 2-8B). The individual ligands, however, 
were only able to activate the reporter ~2.5-3 fold compared to the ~6-8 fold induction found 
with TGFβ and LPA (Fig. 2-3A). This suggests that neither ET-1 or CTGF alone could account 
for the TGFβ mediated SRE-Luc activation.  
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Figure. 2-5. Rho kinase inhibitor blocks TGFβ-induced delayed expression of MRTF target 
genes COL1A2 and ACT2.  
Primary human dermal fibroblasts obtained from healthy donors (≤ passage 6) were stimulated 
for 6 and 18 hours with 10ng/mL TGFβ or 6 hours with 10µM LPA in 0.5% serum starved 
medium. To further identify F-actin/MRTF regulated genes 10µM Y-27632 was used to inhibit 
Rho-kinase at each of the ligand stimulation time points. Based on these results the genes were 
again clustered into SMAD target genes, MRTF target genes, or combined SMAD/MRTF target 
genes. Data represents the mean (+/- SEM) of three independent experiments; expression levels 
were quantified relative to GAPDH and normalized to the untreated control. 
49 
 
 
Figure. 2-6. Role of LPA in TGFβ-mediated MRTF activation.  
A.) ENPP2 (Autotoxin) expression profile following TGFβ and LPA treatment. Primary human 
dermal fibroblasts obtained from healthy donors (≤ passage 6) were stimulated for the indicated 
amount of time with 10ng/mL TGFβ or 10µM LPA in 0.5% serum starved medium. RNA was 
analyzed by qPCR to determine relative expression levels of ENPP2. Data represents the mean 
(+/- STD) of two independent experiments; expression levels were quantified relative to GAPDH 
and normalized to the untreated control. B.) LPA Receptor 1/3 antagonist effect on TGFβ and 
non-stimulated MRTF activity. NIH-3T3 cells expressing SRE-luciferase were treated for 24 
hours with the indicated concentrations of KI16425 +/- 10ng/mL TGFβ for 3 hours. All 
luciferase experiments were multiplexed with WST-1 to monitor cellular proliferation/toxicity 
and data represents the mean (+/- SEM) of luciferase luminescence relative to WST-1 
absorbance and normalized to the untreated control of three independent experiments. 
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Figure. 2-7. CTGF and ET-1 stimulate actin stress fibers and MRTF/SRF activity.  
A.) NIH-3T3 fibroblasts were starved for 24 hours and stimulated for 1 hour with exogenous 
CTGF (10µg/mL) and/or ET-1 (1µM). F-actin was stained along with DAPI nuclear staining and 
four images from each experiment were examined for cells which displayed F-actin stress fiber 
formations. Data represents the mean (+/- STD) from three independent experiments. Shown are 
representative images from each condition. Scale bar represents 100µm. B.) CTGF and ET-1 
dose response curves for activation of MRTF/SRF luciferase. NIH-3T3 fibroblasts were 
transfected with MRTF specific SRE-Luciferase reporter plasmid and treated with the indicated 
concentrations of recombinant ET-1 and/or CTGF for 6 hours. All luciferase experiments were 
multiplexed with WST-1 to monitor cellular proliferation/toxicity and data represents the mean 
(+/- SEM) of luciferase luminescence relative to WST-1 absorbance and normalized to the 
untreated control of three independent experiments. (* P< 0.05, *** P< 0.001 vs. control). (## P< 
0.01 vs. CTGF or ET-1 alone treatment). 
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CTGF and ET-1 signaling are both required for TGFβ stimulated stress fibers and MRTF 
activation.  
 To determine the role of ET-1 and CTGF in inducing stress fibers and MRTF activity 
following TGFβ, we tested the endothelin receptor type A (ETA) antagonist, CI 1020, and a 
neutralizing antibody (NAb) for CTGF. Cells treated for 3 hours with TGFβ produce pronounced 
F-actin stress fiber formation, however treatment with the CTGF NAb or CI 1020 partially block 
this stimulation (Fig. 2-8A). Importantly, combined treatment with the neutralizing antibody and 
ETA receptor antagonist further blocks TGFβ stimulated stress fibers.  Similarly, CTGF NAb and 
CI 1020 were able to partially block MRTF acvity (Fig. 2-8B). Unlike the LPA receptor 
antagonist Ki16425, both the CTGF NAb and CI 1020 have no effect on baseline MRTF activity 
in the absense of TGFβ (Fig. 2-9). Combined treatment with the CTGF neutralizing antibody and 
ETA receptor antagonist produced a significantly greater inhibition of TGFβ stimulated MRTF 
activity than either inhibitor alone. These two mediators together apprear to account for atleast 
~80% of the TGF-β stimulated Rho/MRTF activity. 
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Figure. 2-8. CTGF and ET-1 signaling is essential for TGFβ induced F-actin stress fibers 
and MRTF/SRF gene transcription.  
A.) NIH-3T3 fibroblasts were starved for 24 hours in 0.5% serum medium +/- 10µg/mL CTGF 
neutralizing antibody (CTGF NAb) and/or 100nM ETA antagonist, CI 1020, and stimulated with 
10ng/mL TGFβ for three hours. F-actin was stained along with DAPI nuclear staining and four 
images from each experiment were examined for cells which displayed F-actin stress fiber 
formations. Data represents the mean (+/- STD) from three independent experiments. (* P< 0.05, 
** P< 0.01, *** P<0.001 vs. TGFβ stimulated control).  Shown are representative images from 
each condition. Scale bar represents 100µm. B.) CTGF neutralizing antibody blocks TGFβ 
induced MRTF activity. NIH-3T3 cells expressing SRE-luciferase were treated for 18 hours with 
the indicated concentrations of a CTGF neutralizing antibody and/or 100nM CI 1020 and 
10ng/mL TGFβ. All luciferase experiments were multiplexed with WST-1 to monitor cellular 
proliferation/toxicity and data represents the mean (+/- SEM) of luciferase luminescence relative 
to WST-1 absorbance and normalized to the untreated control of three independent experiments. 
(*** P< 0.001 vs. TGFβ stimulated control). (# P<0.05 vs. CTGF NAb or CI 1020).  
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Figure. 2-9. CTGF neutralizing antibody and endothelin antagonist CI 1020 do not inhibit 
MRTF/SRF activity in the absence of TGFβ.  
NIH-3T3 cells expressing SRE-luciferase were treated for 24 hours with the indicated 
concentrations of A.) CTGF NAb or B.) CI 1020 +/- 10ng/mL TGFβ for 3 hours. All luciferase 
experiments were multiplexed with WST-1 to monitor cellular proliferation/toxicity and data 
represents the mean (+/- SEM) of luciferase luminescence relative to WST-1 absorbance and 
normalized to the untreated control of three independent experiments. 
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Discussion  
 TGFβ continues to garner status as the master cytokine involved in tissue fibrosis 
associated with IPF and systemic sclerosis. Understanding the mechanisms that mediate TGFβ 
driven fibrosis is therefore extremely crucial. Transcriptional programs that mediate the 
transformation of myofibroblasts have potential to be prime targets to treat these diseases; here 
we set out to characterize the activation of MRTF/SRF regulated gene expression downstream of 
TGFβ. The pathways following TGFβ receptor activation involve a complex crosstalk between 
canonical and non-canonical signaling (38).  These networks are separated not only by the 
mediators which traffic the signals but also temporally, as we show here. One important non-
canonical mediator downstream of TGFβ signaling is Rho GTPase. Previous work has shown 
that TGFβ activates hallmarks of Rho signaling; actin stress fiber formations, ROCK 
phosphorylation, and MRTF/SRF gene transcription (27-29). As shown here, TGFβ mediated 
activation of Rho-kinase dependent stress fibers peaked around three hours, but it was also 
relatively stable out to 24 hours. In contrast, LPA induces a rapid but transient activation of Rho-
GTPase peaking within two minutes but turned off within ten (39). GPCR deactivation is carried 
out through a variety of mechanisms involving receptor phosphorylation, internalization, leading 
to either recycling or degradation (40). Endothelin (ET-1), which was shown to play a role as one 
mediator of TGFβ induced stress fibers also signals through a GPCR, ETA.  One major 
difference between LPA and ET-1 in this system however is the magnitude to which they can 
activate MRTF/SRF-mediated gene transcription (8 vs. 3 fold respectively).  
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 The F-actin stress fibers and MRTF/SRF activation following TGFβ stimulation were 
completely blocked by Rho-kinase (ROCK) inhibitor Y-27632. This efficacy is also evident in 
previous work in vitro (41), as well as in vivo, in models of IPF (42), and hepatic fibrosis (43).  
One potential problem for selective ROCK inhibitors as they move towards clinical trials 
however is they have previously been found to only partially inhibit MRTF/SRF gene 
transcription depending on what level the pathway is stimulated (44,45).  
 The effects of the ROCK inhibitor also helped differentiate between SMAD or MRTF 
mechanisms for the profibrotic genes upregulated following TGFβ treatment. Here we saw 
COL1A2 and ACTA2 expression to be dependent on Rho-kinase while COL1A1 and EDN1 to 
be ROCK independent. This was also in agreement with the time course of their expression 
profiles. COL1A2 and ACTA2 were relatively delayed, consistent with the need to produce a 
secondary mediator to activate Rho and MRTF. CTGF however was identified as being regulated 
by both SMAD and MRTF. Within the promoter sequence for CTGF, there are binding elements 
for a variety of transcription factors have been predicted including: SMAD, SRF, AP-1, SP-1, 
and TATA box binding sites (46). Experimentally however, only the SMAD and MRTF/SRF 
binding elements have been functionally shown to induce CTGF expression (47-49). 
Interestingly while the initial expression of CTGF following TGFβ is SMAD-dependent, the 
constitutive expression observed in scleroderma patient derived fibroblasts is independent of 
SMAD (12,49). This is in good agreement with what we find here regarding a shift from SMAD-
regulated expression to MRTF occurring around 12 hours following TGFβ stimulation of 
primary dermal fibroblasts. This also supports the possibility that therapeutic targeting of 
scleroderma patients using TGFβ inhibiting agents may lack efficacy because the genetic 
program has shifted over to a Rho/MRTF mechanisms.  
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 We have highlighted two known TGFβ/SMAD target gene products that are capable of 
stimulating stress fibers and MRTF/SRF-regulated gene transcription, ET-1 and CTGF. Similar 
to LPA, ET-1 signals through GPCRs that can couple to both G12/13 and Gq/11 family G-proteins, 
(50), and in the context of stress fibers and ROCK phosphorylation, both mechanisms maybe be 
important (51). CTGF signaling mechanisms, however, are much less well established, 
especially concerning downstream activation of Rho GTPase. CTGF has been shown to directly 
bind to or signal though fibroblast growth factor receptor 2, tyrosine kinase receptor TrkA, and 
integrins αvβ3, α5β1, α4β1 (37,52-55). Here we find that CTGF is able to stimulate prominent 
stress fiber formation and MRTF/SRF gene transcription very rapidly, similar to GPCR systems. 
It should be acknowledged that CTGF is also functioning as a positive feedback mediator where 
CTGF autocrine signaling stimulates stress fiber formation leading to MRTF/SRF activation that, 
as previously discussed stimulates expression of CTGF.  
 Relevant to therapeutic approaches, we have shown that with combined treatment with an 
endothelin receptor type A antagonist and a CTGF neutralizing antibody almost completely 
blocks the TGFβ mediated stress fiber formation and MRTF activation. Endothelin antagonists 
have been well studied for the treatment of tissue fibrosis (56). Intriguingly, endothelin 
antagonists are clinically approved and have been used with minimal side effects for several 
years. Several clinical trials on the use of non-selective and selective endothelin antagonists 
against IPF and related diseases have been attempted but terminated early due to lack of efficacy 
(57-59). CTGF signaling inhibitors or antagonists have been difficult to develop because of the 
multitude of receptors to which CTGF binds. Preliminary studies determining the efficacy of 
blocking CTGF have used genetic knockdowns and have shown efficacy in models of cardiac, 
renal, and liver fibrosis (60-62). Based on these findings, a humanized anti-CTGF antibody has 
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been developed. Results are currently pending in phase II clinical trials of FG-3029 in IPF 
(ClinicalTrails.gov NCT01890265) and liver fibrosis (ClinicalTrails.gov NCT01217632). Based 
on our findings here, a combined approach of treating patients with a selective ETA receptor 
antagonist and a CTGF neutralizing antibody would provide the greatest efficacy against TGFβ-
mediated fibrosis. An alternative approach would be targeting signaling downstream of Rho, 
where these pathways converge. MRTF/SRF mediated gene transcription has been shown to be 
the essential step activating fibroblasts (30-32). Small-molecule inhibitors for the MRTF 
pathway previously developed in our lab block myofibroblast transformation, expression of pro-
fibrotic genes including CTGF, COL1A2, and ACTA2 in vitro, and show efficacy in 
experimental models of peritoneal, and dermal fibrosis in vivo (63-65).  
 Taken together, these data suggest pro-fibrotic disorders like IPF and scleroderma are 
driven by complex signaling mechanisms which feedback and cross-talk each other through 
spatial and temporal ranges. This essentially offers a multitude of receptors and pathways which 
can be used for targeted therapies but also advocates against blocking a specific upstream 
receptor system as a single therapy. Continued investigations into non-canical and downstream 
mediators of TGFβ and other stimulatory cytokines will lead to well-designed therapeutic 
approaches for these debilitating diseases.  
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Figure. 2-10. Current model of TGFβ stimulation of the Rho/MRTF pathway.   
In the absence of TGFβ, serum starved fibroblasts display very modest activation of the 
Rho/MRTF pathway, mediated by basal levels of LPA. TGFβ treatment produces a rapid 
transcription of SMAD family target genes including EDN1 (ET-1) and CTGF. TGFβ treatment 
reduces expression of ENPP2 (autotaxin) which is responsible for LPA synthesis. Newly 
synthesized ET-1 and CTGF stimulate strong, but delayed activation of the Rho/MRTF pathway. 
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CHAPTER III 
TARGETING THE MYOFIBROBLAST GENETIC SWITCH: INHIBITORS OF 
MRTF/SRF-REGULATED GENE TRANSCRIPTION PREVENT FIBROSIS IN A 
MURINE MODEL OF SKIN INJURY 
Abstract 
Systemic sclerosis (SSc) or scleroderma, like many fibrotic disorders, lacks effective therapies. 
Current trials focus on anti-inflammatory drugs or targeted approaches aimed at one of the many 
receptor mechanisms initiating fibrosis. In light of evidence that a myocardin-related 
transcription factor (MRTF) and serum response factor (SRF)-regulated gene transcriptional 
program induced by Rho GTPases is essential for myofibroblast activation, we explore the 
hypothesis that inhibitors of this pathway may represent novel antifibrotics. MRTF-SRF-
regulated genes show spontaneously increased expression in primary dermal fibroblasts from 
patients with diffuse cutaneous SSc. A novel small-molecule inhibitor of MRTF/SRF-regulated 
transcription (CCG-203971) inhibits expression of connective tissue growth factor (CTGF), 
alpha-smooth muscle actin (α-SMA), and collagen 1 (COL1A2) in both SSc fibroblasts and in 
LPA- and transforming growth factor β (TGFβ)-stimulated fibroblasts. In vivo treatment with 
CCG-203971 also prevented bleomycin-induced skin thickening and collagen deposition. Thus 
targeting the MRTF/SRF gene transcription pathway could provide an efficacious new approach 
to therapy for SSc and other fibrotic disorders. 
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Introduction  
 Systemic sclerosis (scleroderma, SSc) is a multisystem autoimmune disorder that can 
cause fibrosis of the skin and internal organ systems (lungs, heart, kidneys, and gastrointestinal 
system). It has the highest case fatality of any rheumatic disease. SSc predominately affects 
women (4-8:1) and increases with age. The precise pathogenesis of SSc is yet to be defined but 
the major clinical features of SSc— collagen production, vascular damage and 
inflammation/autoimmunity—require environmental triggers and genetic effects which interact 
with the three cardinal features of the disease at several points (1). Generally, there is initial 
inflammation but fibrosis persists even after the inflammation has resolved or has been 
suppressed by medications (2,3). This has led to the concept that understanding and targeting the 
fibrosis mechanism per se will be critical to successful therapies (2-4).  
 A central feature of virtually all diseases of fibrosis is the activation of fibroblasts and 
transition into myofibroblasts (2,4-10). The expression of alpha-smooth muscle actin (α-SMA) is 
a widely recognized marker for this transition but it also contributes to the maintenance of 
fibrosis (4-7,9,11). There are multiple signaling pathways that induce myofibroblast transition. 
TGFβ is a critical mediator but lysophosphatidic acid (LPA), endothelin, thombin, angiotensin, 
and connective tissue growth factor (CTGF) have all been implicated (2-4). Additionally, tissue 
stiffness has been identified as a positive feedback mechanism that leads to further myofibroblast 
activation – probably through integrins and focal adhesion kinase (FAK) mechanisms (2,11,12).  
 Emerging evidence implicates gene transcription induced by serum response factor (SRF) 
as a critical driver of myofibroblast activation by nearly all of these mechanisms (13-15). Indeed, 
key genes involved in fibrosis are direct SRF targets including CTGF, COL1A2, and even 
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ACTA2, the gene for α-SMA itself. This concept of a central role for SRF helps rationalize the 
complex signaling mechanisms that have been implicated in fibrosis. SRF-regulated gene 
expression is dependent on Rho-GTPase stimulated nuclear localization of its transcriptional 
coactivator MRTF. RhoA appears to be a convergent downstream mediator activated by virtually 
all of the signal pathways controlling the of myofibroblast transition (12,13,15,16). G protein-
coupled receptors for LPA, endothelin, thrombin, angiotensin and even chemokines activate 
RhoA (17,18). Other factors important in fibrosis including TGFβ and FAK also modulate 
MRTF/SRF activity through activation of Rho signaling and actin dynamics (19-21) which in 
turn drives expression of connective tissue growth factor (CTGF or CCN2) which synergizes 
with TGFβ in its pro-fibrotic actions (22-24).  Indeed, recent evidence suggests that CTGF 
release from SSc endothelial cells can enhance fibrosis, providing a connection between the 
vascular and mesenchymal attributes of SSc (24). 
 Disruption of the Rho pathway with ROCK inhibitors has reversed myofibroblast 
differentiation in vitro and fibrosis in several animal models (13,14,25-29). We recently 
identified, in high throughput screens, a compound, CCG-1423, which blocks MRTF nuclear 
localization by interfering with the microtubule associated monooxygenase, calponin and LIM 
domain containing 2 (MICAL-2), mediated regulation of intranuclear actin polymerization 
(30,31). CCG-1423 is more effective than ROCK inhibitors in reducing SRF-mediated 
transcription (30). Several groups have used this compound to interdict myofibroblast formation 
(16,29) and it was recently shown to have in vivo activity in a chlorhexidine gluconate model of 
peritoneal fibrosis (20). We have now optimized this chemical series to reduce off-target toxicity 
(32,33). 
66 
 
 In the present study, we demonstrate in human SSc dermal fibroblasts that there is 
spontaneous activation of an MRTF-regulated gene transcription program. CCG-203971, a new 
MRTF/SRF-gene transcription inhibitor, reverses the myofibroblast phenotype of both TGFβ-
stimulated normal dermal fibroblasts as well as the spontaneous activation of SSc-derived 
fibroblasts in vitro. Furthermore, it prevents the development of fibrosis in a mouse bleomycin 
skin injury model. These results suggest that targeting the MRTF/SRF gene transcription 
mechanism may provide a novel and particularly effective approach to antifibrotic therapy. 
 
 
 
 
 
 
 
 
 
 
 
67 
 
Materials and Methods  
Patient sample and Animal Use 
All SSc patients fulfilled the American College of Rheumatology criteria for classification of 
SSc (34). Two punch biopsies (4 mm) were taken from the forearm of mixed sex, SSc patients 
with the diffuse cutaneous variant. Normal skin tissue was obtained similarly from mixed sex, 
healthy volunteers. Written informed consent was obtained for all subjects and the study was 
approved by the University of Michigan Institutional Review Board. All experiments performed 
with animals were done with approval from the University of Michigan Committee on Use and 
Care of Animals. C57BL/6 mice were used for the bleomycin prevention model.   
Primary Cell Culture 
Both normal and SSc dermal fibroblasts were isolated from human skin (ages 53.4±13.1 years 
for SSc; 47.5±18.4 years for normal).  The tissue was digested using enzyme digestion solution 
containing 2.4 units/ml dispase, 650 units/ml type II collagenase, and 10,000 Dornase units/ml 
DNase. Dermal fibroblasts were maintained in DMEM with 10% fetal bovine serum (FBS), 
penicillin, and streptomycin. Cells of passages between 4 and 6 were used.  
qPCR 
Dermal fibroblasts (1.0X10
5
) were plated into 6-well plates (Falcon #353046) and starved for 24 
hours in DMEM containing 0.5% FBS with the indicated concentrations of CCG-203971, 0.1% 
DMSO, and stimulated with 10ng/mL TGFβ1 (R&D Systems). Cells were lysed and RNA was 
isolated using the RNeasy® kit (Qiagen) following the manufacturer’s directions. DNAse-treated 
RNA was quantified using a NanoDrop® spectrophotometer and 1µg was used as a template for 
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synthesizing cDNA utilizing the Taqman® Reverse-Transcription Reagents kit (Invitrogen). 
SYBR green qPCR (SABiosciences) was performed using a Stratagene Mx3000P (Agilent 
Technologies). Ct values were determined and mRNA expression calculated relative to that of 
GAPDH. Primer sequences were: GAPDH; 5’ GGAAGGGCTCATGACCACAG. 3’ 
ACAGTCTTCTGGGTGGCAGTG. CTGF; 5’ CAGAGTGGAGCGCCTGTT. 3’ 
CTGCAGGAGGCGTTGTCA. ACTA2; 5’ AATGCAGAAGGAGATCACGC. 3’ 
TCCTGTTTGCTGATCCACATC. COL1A2-hn; 5’ CTTGCAGTAACCTTATGCCTAGCA. 3’ 
CCCATCTAACCTCTCTACCCAGTCT. EDN1; 5’ CTTCGTTTTCCTTTGGGTTCAG.  3’ 
GCTCAGCGCCTAAGACTG. COL1A1-hn; 5’ CTTGCAGTAACCTTATGCCTAGCA. 3’  
CCAACTCCTTTTCCATCATACTGA. All mRNA values were normalized to a control (either 
normal fibroblasts or a vehicle control) run the same day.  
Proliferation 
Human dermal fibroblasts (2.0X10
4
) were plated into a 96-well plate and grown overnight in 
DMEM containing 10% FBS. Media was removed and replaced with DMEM containing 2% 
FBS and 30µM CCG-203971 or 0.1% DMSO control. After 72 hours WST-1 dye was added to 
each well according to the manufacturer and after 60 minutes absorbance at 490nm was read 
using a Wallac Victor II plate reader.  
Immunocytochemistry 
Dermal fibroblasts (3.0X10
4
) from normal individuals or from patients with diffuse SSc were 
plated on 20mm glass cover slips in DMEM containing 10% FBS and allowed to attach 
overnight. Medium was changed to low-serum medium (DMEM with 0.5% FBS) for 72 hours 
with the indicated concentration of CCG-203971 (and 0.1% DMSO control) with or without 
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stimulation by 10 ng/mL TGFβ1 (R&D Systems, Minneapolis, MN). The 3-day time point was 
chosen because in initial experiments TGFβ did not induce significant myofibroblast transition at 
24 hours (data not shown). Cells were then fixed in 3.7% formaldehyde for 10’ at room 
temperature and permeabilized with 0.25% Triton X-100 for 10’ at room temperature (RT). 
Primary antibody for α-SMA (ab5694, Abcam, Cambridge, MA) was diluted 1:300 and 
incubated for 2 hours at RT. Fluorophore-conjugated secondary antibody (Alexa Fluor® 594 
goat anti-rabbit IgG, Invitrogen, Carlsbad, CA) was diluted 1:1,000 and added for 1 hour at RT. 
Cover slips were mounted (Prolong Gold ® antifadereagent with DAPI, Invitrogen) and imaged 
on an upright fluorescence microscope (Nikon E-800) at 40X magnification. For quantification; 
cells from three, random non-overlapping fields of view were scored as α-SMA positive or 
negative by an observer blinded to the treatment.  
Bleomycin-induced skin fibrosis model 
Skin fibrosis was induced in C57BL/6 mice (female, 8 weeks old) by local intracutaneous 
injection of 100 μL of bleomycin (1 mg/ml) in phosphate-buffered saline (PBS), every day for 2 
weeks in a defined area (~ 1 cm
2) on the upper back. Intracutaneous injection of 100 μL PBS was 
used as a control. Three groups of mice with a total of 21 mice were used. One group received 
injections of PBS, and the other two were challenged with bleomycin. Twice-a-day 
intraperitoneal administration of CCG-203971 (100 mg/kg in 50 μL DMSO) was initiated 
together with the first challenge of bleomycin and continued for 2 weeks. DMSO was used as the 
vehicle control. The three groups of animals were: (1) PBS/DMSO; (2) bleomycin/DMSO; (3) 
bleomycin/CCG-203971. After treatment, animals were sacrificed by cervical dislocation and 
tissue was collected.  
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Histology analysis 
Skin obtained from the upper back at the site of the Bleomycin or PBS injections was fixed and 
embedded in paraffin at the University of Michigan Comprehensive Cancer Center Histology 
Core. Skin sections were stained with Masson's trichrome. Dermal thickness was determined by 
measuring the maximal distance between the epidermal-dermal junction and the dermal-
subcutaneous fat junction. Three measurements were averaged from each skin section. The 
measurement was performed using the analysis tool in Photoshop. 
Hydroxyproline assay 
The collagen content from lesional skin samples was quantified using a hydroxyproline assay kit 
from Sigma (St. Louis, MO), and normalized with tissue weight. 
Statistics 
Statistical analysis for two-group comparisons used a two-tailed, unpaired t-test. For three or 
more groups analysis was performed by one-way ANOVA in GraphPad Prism (La Jolla, CA) 
followed by a Bonferroni posttest comparing all pairs in the dataset. Statistical significance was 
defined as p<0.05. 
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Results 
LPA and TGFβ activate the Rho/MRTF/SRF transcriptional pathway and stimulate expression of 
pro-fibrotic genes in NIH-3T3 fibroblasts. 
 LPA (10µM, 6 hours), and TGFβ (10ng/mL, 18 hours) treatment of NIH-3T3 fibroblasts 
activates MRTF specific SRF gene expression and the previously described MRTF/SRF pathway 
inhibitor CCG-203971 (32) blocked this activation (Fig. 3-1A). The magnitude for TGFβ vs. 
LPA activation of MRTF was 4 and 5 fold respectively, and the IC50 for the inhibition by CCG-
203971 was ~2.5µM. LPA treatment of NIH-3T3 fibroblasts also stimulates expression of 
several Rho-regulated, pro-fibrotic genes (Fig. 3-1B).  Levels of mRNA for CTGF and ACTA2, 
both known MRTF/SRF targets, were induced 1.5- and 17.5-fold, respectively. Similarly, the 
heterogeneous nuclear precursor RNA for COL1A2 (COL1A2-hn), another MRTF/SRF target 
gene was also increased by LPA (4.6-fold). Induction of all three genes was blocked by CCG-
203971 in a concentration-dependent manner. The IC50 for these effects is ~1-3 μM. As a follow-
up to Fig. 2-5 found in Chapter II, we also tested the ability of CCG-203971 to block expression 
of LPA and TGFβ stimulated gene expression in primary human dermal fibroblasts obtained 
from healthy donors (Fig. 3-2). Unlike the results with the ROCK inhibitor Y-27632, we found 
CCG-203971 blocked the induction of profibrotic genes under all conditions, 6 hour stimulation 
with LPA and 24 hour stimulation with TGFβ.  
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SSc dermal fibroblasts overexpress MRTF/SRF target genes.  
 Multiple MRTF/SRF target genes are both markers and drivers of dermal fibrosis. CTGF, 
ACTA2 and COL1A2 are overexpressed in the SSc dermal fibroblasts when compared to the 
normal donor samples (Fig. 3-3A). To further assess the involvement of the MRTF/SRF pathway 
in pro-fibrotic gene expression we treated the SSc cells with increasing concentrations of our 
MRTF/SRF pathway inhibitor, CCG-203971, which reduced expression of CTGF, ACTA2, and 
COL1A2 (Fig. 3-3B). In light of the long half-life of mRNA for COL1A2, the primers were 
designed to amplify the 1st exon/intron border of the gene (COL1A2-hn). About 50% inhibition 
of these MRTF/SRF target genes was seen with 10 μM CCG-203971. Pirfenidone, which is the 
only approved therapy directly targeting fibrosis, significantly inhibited ACTA2 gene expression 
but only showed a trend toward inhibition of CTGF and COL1A2-hn. The pirfenidone effect, 
however, required a concentration of 300 μM which is 30-100 times greater than the effective 
concentrations of CCG-203971.  
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Figure 3-1. TGFβ and LPA activate MRTF/SRF and pro-fibrotic gene expression in 3T3 
fibroblasts in a Rho/MRTF-dependent manner.  
A.) NIH-3T3 cells were transiently transfected with a MRTF specific, SRF reporter (SRE-Luc.) 
then treated with the indicated concentrations of CCG-203971 overnight, then stimulated with 
TGFβ (10ng/mL, 18 hours) or LPA (10µM, 6 hours). Prior to cell lysis and luminescence 
reading, WST-1 viability reagent was added to each well to control for cellular proliferation and 
compound toxicity. Data shown are the mean, ±SEM relative to viability, expressed as a 
percentage of the change compared to the DMSO control of three independent experiments. B.) 
NIH-3T3 cells were treated with the indicated concentration of CCG-203971 or DMSO for 23 
hours. One hour prior to RNA isolation, cells were stimulated with 10µM LPA. Expression of 
MRTF target genes CTGF, ACTA2, and COL1A2 was assessed by qPCR. For COL1A2, primers 
were designed to amplify newly synthesized heterogeneous nuclear RNA (hnRNA). Expression 
levels were quantified relative to GAPDH. Data are mean, ±SD of two independent experiments. 
(Reproduced with permission from The Journal of Pharmacology and Experimental 
Therapeutics)  
 
74 
 
 
Figure. 3-2. The Rho/MRTF pathway inhibitor CCG-203971 prevents pro-fibrotic gene 
expression.  
Primary human dermal fibroblasts obtained from healthy donors (≤ passage 6) were stimulated 
for 6 and 24 hours with 10ng/mL TGFβ or 6 hours with 10µM LPA in 0.5% serum starved 
medium +/- 10µM CCG-203971. Based on previous findings the genes were clustered into 
SMAD target genes, MRTF target genes, or combined SMAD/MRTF target genes. Data 
represents the mean (+/- SEM) of three independent experiments; expression levels were 
quantified relative to GAPDH and normalized to the untreated control. 
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Figure. 3-3. SSc patient dermal fibroblasts show increased expression of fibrosis 
markers/MRTF target genes which are inhibited by CCG-203971.  
A.) mRNA expression for fibrotic markers: connective tissue growth factor (CTGF), alpha 
smooth muscle actin (ACTA2), and collagen (COL1A2) were quantified by qPCR. Primary 
human dermal fibroblasts isolated from normal donors or patients with SSc were grown in 
culture for no more than 5 passages prior to mRNA isolation. Data are mean ±SEM of samples 
from three individuals. B.) CCG-203971 treatment reduces expression of CTGF, ACTA2, and 
COL1A2. Prior to mRNA isolation, SSc dermal fibroblasts were treated for 24 hours in the 
presence of the indicated concentration (µM) of CCG-203971 or 300 µM pirfenidone (PFD). 
Data are mean ±SEM of samples from at least four individuals. (* P< 0.05, ** P< 0.01, *** 
P<0.001, **** P<0.0001 vs. DMSO control.) (Reproduced with permission from The Journal of 
Pharmacology and Experimental Therapeutics) 
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Scleroderma fibroblasts proliferate faster than normal cells and CCG-203971 selectively blocks 
their growth. 
 Autocrine secretion of LPA and overexpression of mitogenic cytokines like CTGF 
contributes to cell proliferation in fibrotic tissues (35,36). SSc cells proliferated faster than 
normal dermal fibroblasts and this increase in growth was selectively blocked by CCG-203971 
(Fig. 3-4). Combined with the effect on gene expression, these data suggest that the MRTF/SRF 
pathway is important for the transition of normal dermal fibroblasts into the faster proliferating 
myofibroblast-like SSc cells.  
 
Inhibition of the MRTF/SRF pathway modulates myofibroblast transition of dermal fibroblasts. 
 α-SMA is involved in cellular motility and the contractile apparatus. It is also a well-
recognized protein marker for myofibroblasts (11,12,27). Dermal fibroblasts from normal donors 
exhibit TGFβ-stimulated α-SMA expression which is blocked by CCG-203971 (Fig. 3-5A,C). In 
these experiments at 72 hours, 10 μM completely blocks the myofibroblast transition of normal 
fibroblasts. Consistent with the mRNA expression data above, SSc patient-derived fibroblasts 
display spontaneously high levels of α-SMA protein which can be reversed by treatment with 
CCG-203971 (Fig. 3-5B,C). Here also, pirfenidone reversed the α-SMA expression but with a 
50% reduction occurring at 300 µM pirfenidone; it is 100X less potent than CCG-203971 which 
shows an IC50 of ~3 μM in this assay (Fig. 3-5C). 
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Figure. 3-4. Scleroderma dermal fibroblasts proliferate faster than normal cells and this is 
inhibited by CCG-203971.  
Cells were plated onto 96-well plates and allowed to grow for 3 days in the presence of 30 µM 
CCG-203971 or DMSO vehicle. Viable cell density was assessed through enzymatic reduction 
of the water-soluble tetrazolium dye WST-1. Data are mean ±SEM of samples from three 
individuals. (* P< 0.05 vs. DMSO treated nomal, # # P< 0.01 vs. DMSO treated SSc.) 
(Reproduced with permission from The Journal of Pharmacology and Experimental 
Therapeutics) 
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Figure. 3-5. CCG-203971 modulates myofibroblast transition of dermal fibroblasts.  
A.) Primary human dermal fibroblasts from normal donors were plated onto coverslips and 
treated with or without 10ng/mL TGFβ for three days to induce a myofibroblast transition; 
during stimulation cells were also treated with 10 µM CCG-203971 or DMSO. Cells were then 
fixed and α-SMA was visualized using immunocytochemistry along with nuclear DAPI staining. 
Shown are two representative individual samples.  
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Figure. 3-5. (continued) B.) Human dermal fibroblasts from diffuse SSc patients were plated 
onto coverslips and treated with the indicated concentration of CCG-203971. Cells were then 
fixed and visualized using immunocytochemistry along with nuclear DAPI staining. Shown are 
two representative individual samples. C.) The fraction of cells positive for α-SMA was scored 
by an observer blinded to the sample identification. Data are mean ±SEM of samples from at 
least four individuals. (* P< 0.05, *** P<0.001, vs. DMSO Scleroderma, +++ P< 0.001 vs. 
Normal DMSO, &&& P< 0.001 vs. Normal TGFβ) (Reproduced with permission from The 
Journal of Pharmacology and Experimental Therapeutics) 
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CCG-203971 blocks dermal fibrosis in bleomycin induced injury model 
To determine whether these effects would translate in vivo, we tested CCG-203971 in a 
bleomycin skin injury model. Due to its modest solubility, it was administered in 50 μL DMSO 
intraperitoneally. Preliminary studies showed that the compound administered in this manner 
was well-tolerated at 100 mg/kg twice a day. Intradermal bleomycin for two weeks along with 
the DMSO control (50 μL i.p.) resulted in marked dermal thickening (p<0.0001) compared to the 
PBS+DMSO group which did not receive bleomycin (Fig.3-6A-B). CCG-203971 treatment 
strongly and significantly (p<0.001) suppressed the bleomycin-induced skin thickening in this 
model (Fig. 3-6A-B). Skin collagen amounts, assessed by measurement of hydroxyproline 
content, showed similar results. Bleomycin injections promoted collagen deposition (p<0.01) and 
CCG-203971 was able to block this effect (p<0.05, Fig. 3-6C).  
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Figure. 3-6. CCG-203971 prevents bleomycin-induced fibrosis in vivo.  
Bleomycin (0.1 mg) or vehicle (PBS) were injected intradermally in three groups of seven 
C57BL/6J mice for two weeks. Mice were also treated with twice daily i.p. injections of either 
CCG-203971 (100 mg/kg) or vehicle control (DMSO 50 μL). At the end of the treatment period, 
skin samples were collected and either stained with Masson’s trichrome (panels A and B) or 
analyzed for hydroxyl-proline content (panel C) as described in Materials and Methods. 
Differences in skin thickness (triplicate measures from each mouse) and hydroxyproline content 
were assessed by one-way ANOVA with the Bonferroni post-test to correct for multiple 
comparisons. (** P< 0.01, **** P<0.0001, Bleomycin vs. PBS control, + P<0.05, +++ P< 0.001 
Bleo & CCG-203971 vs. Bleo & DMSO) (Reproduced with permission from The Journal of 
Pharmacology and Experimental Therapeutics) 
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Discussion  
 There are no effective therapeutics for SSc and only very recently have therapeutics been 
approved for the treatment of other diseases with fibrosis as a primary feature. Most current 
approaches target the inflammation that initiates fibrosis but don’t directly address the process of 
fibrosis per se. In light of recent evidence for a central role of gene transcription regulated by the 
MRTF/SRF complex, we now show that an inhibitor of this mechanism can reverse 
myofibroblast differentiation and reduce the fibrosis response in a bleomycin skin injury model. 
 In recent years, important signaling pathways of fibrosis have been elucidated (2-4). 
Some key receptors that drive fibrosis include those for TGFβ, lysophosphatidic acid (LPA1), 
endothelin, angiotensin (AT1), chemokines (CXCR4), and serotonin (5HT2). In addition, tissue 
stiffness itself can activate integrins and focal adhesion kinase which set up a vicious cycle to 
maintain fibrosis after the initial inflammatory stimulus is resolved (21,37). Many of these 
mechanisms are currently under consideration as antifibrotic targets (2-4,38). However, blocking 
each individual signal may not be effective. Indeed despite good preclinical results (39), TGFβ-
1-neutralizing antibodies failed to show efficacy in SSc (40).  
 Targeting downstream mechanisms that are engaged by multiple fibrotic inputs may be 
more effective. Epigenetic mechanisms provide one promising avenue of this type with histone 
deacetylase and DNA methyltransfease inhibitors (3,41). Similarly kinase inhibitors such as 
imatinib have been considered but recent clinical trials showed conflicting results (42-44). Rho 
kinase (ROCK) inhibitors have also been used to reduce fibrosis (29). Our compounds, however, 
are more effective in reducing MRTF/SRF-regulated gene transcriptional signaling than is the 
ROCK inhibitor Y-27632 (30). 
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 We propose here that the Rho/MTRF/SRF transcription mechanism may represent an 
important downstream target for anti-fibrotic therapy. Our results with CCG-203971 in vitro and 
in vivo are promising. The strong effect to inhibit CTGF expression and collagen synthesis and 
the reduction in myofibroblast differentiation induced by both TGFβ and LPA suggests that we 
are engaging a key step in the overall fibrosis gene program. Since this family of compounds 
blocks nuclear localization of MRTF-A and SRF-regulated gene expression regardless of the 
activating stimulus (30), it should have actions against many pro-fibrotic ligands. CCG-203971 
was tolerated at the relatively high doses used in our study. The potency of this compound in 
vitro is only modest (IC50 1-3 μM for most effects) but compared to the only approved anti-
fibrotic drug, pirfenidone, it is nearly 100x more potent (see Fig.3-5C). Unlike pirfenidone, the 
direct molecular target of CCG-1423 to which CCG-203971 is related, was recently identified 
(31). This should facilitate the development of new, more potent analogs.  
 RNAi-mediated MRTF knock-down produces strong antifibrotic effects in several 
models (13,15,16,29), which provides important target validation for this pathway. Perhaps the 
greatest limitation currently is the very short in vivo half-life of CCG-203971 (T1/2 ~25 minutes 
after i.p. administration, data not shown). Improvements to its pharmacokinetic properties will 
clearly facilitate clinical translation. 
 The Rho/MRTF/SRF-regulated transcription pathway plays a critical role in fibrosis by 
switching on the myofibroblast state. Many different fibrosis signals that are targets of current 
therapeutic development feed into this pathway. This mechanism is spontaneously active in 
human dermal fibroblasts from diffuse SSc patients. We show that a novel small molecule 
inhibitor of MRTF/SRF-regulated gene transcription, CCG-203971, reverses myofibroblast 
activation and collagen synthesis by human SSc dermal fibroblasts and by LPA- and TGFβ-
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stimulated fibroblasts.  It also prevents skin thickening and collagen deposition in a bleomycin 
skin injury model. Consequently, MRTF/SRF transcription pathway inhibitors may represent an 
efficacious new approach to SSc and other diseases of fibrosis. 
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CHAPTER IV 
PHARMACOLOGICAL INHIBITION OF MYOCARDIN-RELATED 
TRANSCRIPTION FACTOR PATHWAY BLOCKS LUNG METASTASIS OF RHOC 
OVEREXPRESSING MELANOMA 
Abstract 
Melanoma is the most dangerous form of skin cancer with the majority of deaths arising from 
metastatic disease. Evidence implicates Rho-activated gene transcription, mediated by the 
nuclear localization of the transcriptional coactivator, myocardin-related transcription factor 
(MRTF), in melanoma metastasis. Here, we compare in vitro and in vivo models of cancer 
metastasis (clonogenicity, migration, invasion, and murine lung colonization) to Rho expression 
and signaling in a panel of human metastatic melanoma cell lines. Three melanoma lines (two 
NRAS mutant and one BRAF mutant) show evidence of high RhoC expression and activity 
(stress fiber formation, spontaneous nuclear localization of MRTF-A, and increased MRTF 
regulated gene expression); they also show an aggressive phenotype in cellular models. 
Conversely, the other two BRAF mutant melanoma lines have low RhoC expression, decreased 
levels of MRTF-regulated genes, and display reduced migration, invasion, and clonogenicity.  To 
probe the MRTF transcriptional mechanism, we utilized a previously developed small molecule 
inhibitor, CCG-203971 which at low µM concentrations blocks nuclear localization and activity 
of MRTF-A. CCG-203971 inhibited cellular migration and invasion, and decreased MRTF target 
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gene expression. In an experimental model of melanoma lung metastasis, a RhoC-overexpressing 
melanoma (SK-Mel-147) exhibited pronounced lung colonization compared to the low RhoC-
expressing SK-Mel-19. Furthermore, pharmacological inhibition of the MRTF pathway with 
CCG-203971 reduced both the number and size of lung metastasis resulting in a marked 
reduction of total lung tumor burden. These data link RhoC signaling with aggressive phenotypes 
and support targeting the MRTF transcriptional pathway as a novel approach to melanoma 
therapeutics. 
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Introduction  
 Rho GTPases play significant roles in human cancer (1). Although RhoA and RhoC share 
considerable homology, they may coordinate different aspects of cancer progression. RhoC 
appears to be most important for cellular invasion and metastasis (2) while RhoA plays a role in 
transformation and tumor proliferation (3). In a screen designed to identify genes important for 
melanoma metastasis, RhoC was found to be up regulated and contributed to melanoma lung 
metastasis (4). Rho GTPases are well-known for regulating the actin cytoskeleton (5). RhoA/C 
activation causes the formation of myosin-rich F-actin bundles called stress fibers through their 
downstream effectors Rho associated kinase (ROCK) and Diaphanous-related formin-1 (mDia1) 
(6-8). Through their modulation of the actin cytoskeleton, Rho GTPases also regulate gene 
expression though myocardin-related transcription cofactors (MRTF-A/B) also known as 
megakaryoblastic leukemia genes (MKL1/2). In the nucleus MRTF cooperates with serum 
response factor (SRF) to induce transcription of genes involved in proliferation, migration, 
invasion, and metastasis (9,10). On the N-terminal region of MRTF are three G-actin binding 
(RPEL) motifs which sequester MRTF in the cytoplasm. Rho activity reduces cytosolic G-actin, 
allowing MRTF to translocate into the nucleus and activate gene transcription. Stable 
knockdown of MRTF or SRF in B16M2 melanoma cells with high RhoC expression results in a 
dramatic reduction of in vivo lung metastasis and in vitro cellular migration (11). This evidence 
suggests that gene regulation through MRTF mediates RhoC-induced cancer metastasis.  
 To assess the role of MRTF-regulated gene transcription in cancer metastasis, we 
previously identified small-molecule inhibitors of the MRTF pathway (12). Our initial 
compound, CCG-1423 selectively blocked Rho GTPase-regulated melanoma invasion at low 
micro-molar concentrations. Further SAR optimization of this compound series to reduce 
93 
 
toxicity (13) and to enhance potency (14) resulted in a new analog, CCG-203971 that blocks 
MRTF-induced gene expression and prostate cancer migration without cytotoxic effects. The 
Rho/MRTF pathway has also recently been highlighted as a major signaling crossroad in the 
development of pathological fibrosis in diseases including idiopathic pulmonary fibrosis, 
scleroderma, and Crohn’s disease (15-17). We have recently shown efficacy of CCG-203971 in a 
murine model of skin fibrosis (18) but a close examination of MRTF pathway inhibitors in 
models of cancer progression has not been performed. Two potential molecular mechanisms for 
inhibition of the MRTF/SRF by CCG-1423 have been identified. CCG-1423 has been shown to 
bind MRTFA/B blocking the interaction with nuclear import mechanisms (19). Additionally, 
CCG-1423 binds to MICAL-2, a nuclear actin regulator (20). Either of these molecular 
mechanisms could account for the inhibition of nuclear accumulation of MRTF-A (12,21). 
 Here we investigate the Rho/MRTF pathway in a panel of five human, metastatic 
melanoma cell lines; SK-Mel-19, SK-Mel-29, SK-Mel-147, SK-Mel-103, and UACC-257. There 
is a clear dichotomy among the lines where high levels of RhoC expression, MRTF-A nuclear 
localization and function are closely associated with in vivo and in vitro correlates of cancer 
metastasis including clonogenicity, migration, and invasion. As a novel approach to anti-
metastasis therapeutics, our MRTF pathway inhibitor, CCG-203971, blocks cellular migration 
and invasion as well as in vivo lung colonization in a murine tail vein injection model.  
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Materials and Methods  
Cell Culture and Proliferation  
Human cutaneous melanoma cell lines, SK-Mel-19, SK-Mel-29, SK-Mel-103, SK-Mel-147, and 
UACC-257, obtained from Dr. Maria Soengas, were cultured in DMEM (Life Technologies) 
supplemented with 10% fetal bovine serum (Life Technologies) including 
penicillin/streptomycin (Life Technologies). For proliferation experiments 20,000 cells were 
plated into 24-well plates in DMEM containing 10% FBS. Cells were allowed to attach 
overnight and then medium was replaced with DMEM containing 2% FBS. After 24 or 94 hours 
of growth, cells were suspended and stained with 0.4% trypan blue stain (Invitrogen). Cell 
counting was performed using the Countess® Automated Cell Counter (Invitrogen) according to 
manufacturer’s instructions.  
Immunocytochemistry and F-actin staining 
Cells (1.0X10
5
) were plated onto fibronectin-coated cover slips in 10% FBS DMEM and allowed 
to attach overnight. Medium was changed to 0.5% FBS DMEM for 24 hours with the indicated 
concentration of CCG-203971 or 0.1% DMSO. Cells were then fixed in 3.7% formaldehyde for 
10’ at room temperature (RT) and permeabilized with 0.25% Triton X-100 for 10’ at RT. For 
immunocytochemistry studies, primary antibody for MRTF-A (Santa Cruz Biotechnology SC-
418) was diluted 1:100 and incubated for 2 hours at RT. Fluorophore-conjugated secondary 
(Alexa Fluor® 594 Donkey Anti-Goat IgG, Invitrogen) was diluted 1:1,000 and added for 1 
hour. For stress fiber assays, one unit of Acti-Stain® phalloidin (Cytoskeleton) was added to 
each cover slip for 30’ at RT. Cells were mounted (Prolong Gold ® antifadereagent with DAPI, 
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Invitrogen) and imaged on an upright fluorescence microscope (Nikon E-800) at 60X 
magnification. 
Real-time PCR 
Cells (1.0X10
6
) were plated into 60 mm dishes and starved overnight in DMEM containing 0.5% 
FBS. Cells were lysed and RNA was isolated using the RNeasy® kit (Qiagen) following the 
manufacturer’s directions. DNAse-treated RNA (1 µg) was used as a template for synthesizing 
cDNA utilizing the Taqman® Reverse-Transcription Reagents kit (Invitrogen). SYBR green 
qPCR (SABiosciences) was performed using a Stratagene Mx3000P (Agilent Technologies) and 
cT values were analyzed relative to GAPDH expression. Primer sequences: GAPDH; 5’ 
GGAAGGGCTCATGACCACAG. 3’ ACAGTCTTCTGGGTGGCAGTG. CTGF; 5’ 
CAGAGTGGAGCGCCTGTT. 3’ CTGCAGGAGGCGTTGTCA. CYR61; 5’ 
CGCGCTGCTGTAAGGTCT. 3’ TTTTGCTGCAGTCCTCGTTG. MYL9; 5’ 
CATCCATGAGGACCACCTCCG. 3’ CTGGGGTGGCCTAGTCGTC.  
Scratch Assay 
Cells (4.0X10
5
) were plated in DMEM containing 10% FBS and grown to confluence in a 12-
well plate. After 24 hours, a scratch was made using a 200 µL pipette tip. Medium was replaced 
with DMEM containing 2.0% FBS and images of the wound were taken at time=0 and 24 hours 
using a bright field microscope (Olympus CKX41). Area quantification of the scratch was 
determined using ImageJ software as previously described (14,22). Briefly, the binary (white and 
black) threshold for each image was manually adjusted to leave only the open area of the scratch 
black. The area of this open area was then determined and the percent closure was calculated by 
comparing the difference in area of t=24 from t=0.  
96 
 
Transwell Migration Assay 
Cells (5.0X10
4
) were added to the top of an 8 µm pore diameter transwell chamber (Millipore) in 
DMEM containing 0.5% FBS with 10 µM CCG-203971 or 0.1% DMSO control. Medium 
containing 0.5% FBS and compound or DMSO was also added to the bottom chamber. Cells 
were allowed to migrate for 6 hours followed by fixation and staining in 4% formaldehyde/0.5% 
crystal violet. The number of migrated cells for each well was determined by examining four 
random non-overlapping fields of view at 20X magnification using a bright field microscope 
(Olympus CKX41). 
Label-Free Migration and Invasion Assay 
Real-Time Cell Analysis (RTCA) of cell migration and invasion was monitored using a CIM-
plate 16 and xCELLigence DP System (Acea Bioscience, Inc.). Prior to cell seeding, RPMI 
containing 0.5% fetal bovine serum (Atlas Biologicals) was placed in the upper and lower 
chambers and allowed to equilibrate for 1 hour in an incubator at 37°C in 5% CO2. For 
migration, cells (3 x 10
5
/well (invasion) and 5 x 10
5
/well (migration)) were placed in the upper 
chamber. After cell seeding, the CIM-plate 16 was equilibrated for 30 minutes at room 
temperature. The invasion assay was executed similarly, however to the upper chamber, 5% (v/v) 
Matrigel™ Matrix (BD BioSciences; diluted 1:20 in basal RPMI media) was added and allowed 
to equilibrate for 4 hours in an incubator at 37°C in 5% CO2. For compound effects in invasion 
assays, cells were treated with 10 μM CCG-203971 upon placement into the upper chamber. Cell 
index was measured every 30 minutes. 
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Luciferase Assay 
Cells (3.0X10
4
) were seeded into 96-well plates in DMEM containing 10% FBS overnight. Cells 
were then cotransfected with 56 ng SRE- Luciferase reporter selective for Rho/MRTF described 
in ref. (23), and 2.3 ng RhoC plasmid diluted with Lipofectamine 2000 (Invitrogen) in Opti-
MEM (Life Technologies). After 6 hours, compounds were added for overnight treatment. The 
next day WST-1 (10 µL/well) reagent (Promega) was added to measure viability. After 1 hour, 
absorbance was read (490 nm) before lysing the cells for luciferase measurement (Promega 
Luciferase Assay System).  
Clonogenic Assay 
Cells were grown for 6 days in 2.0% FBS DMEM. Two hundred live cells, determined by trypan 
blue exclusion assay,  were seeded into a 6-well plate and allowed to form colonies in DMEM 
containing 2.0% FBS for 10 days. Colonies were fixed and stained in 3.7% formaldehyde/0.5% 
crystal violet 10 minutes at room temperature. Only cell clusters consisting of at least 50 cells 
were counted as colonies.  
Western Blot Analysis  
Cells were starved overnight in DMEM containing 0.5% FBS, protein lysates (40 µg) were 
resolved using 15% SDS-PAGE gels, transferred to PVDF membranes, and blocked in 5% dried 
milk in tween tris-buffered saline. Membranes were incubated in 1:1000 diluted primary 
antibodies RhoA (Santa Cruz Biotechnologies, sc-418), RhoC (Cell Signaling, D40E4) or 
GAPDH (Cell Signaling, 14C10) overnight at 4º C. HRP-conjugated goat anti-mouse (Santa 
Cruz Biotechnology, sc-2060) or HRP-conjugated goat anti-rabbit (Sigma-Aldrich, A0545) 
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antibodies were diluted 1:10,000. Blots were developed using SuperSignal® Pico 
chemiluminescent substrate (Thermo Scientific). Bands were visualized and quantified using a 
Li-Cor Odyssey Fc.  
Mouse Metastasis Model 
Ten-week old, female, NOD.CB17-Prkdc
scid
/J (NOD SCID) mice were purchased from Jackson 
Laboratory Bar Harbor, ME (stock number: 001303). The mice were separated into three groups 
of six. One group received tail vein injection of GFP-expressing SK-Mel-19 (2X10
6
 cells). The 
other two groups were injected with GFP-expressing SK-Mel-147 (2X10
6
 cells). Following tail 
vein injection, the mice began twice daily I.P. injection of 100 mg/kg CCG-203971 or 50μL 
DMSO (vehicle control). After 18 days the mice were euthanized and lungs were collected for 
histological analysis. All studies were performed according to protocols approved by the 
University of Michigan, University Committee on the Use and Care of Animals (UCUCA).  
Immunohistochemistry 
For the quantification and imaging of lung tissue from the mouse metastasis model, paraffin-
embedded sections were dewaxed, unmasked, and treated as previously described (24). To 
visualize GFP-expressing melanoma cells in the lung section, the Vector Rabbit-on-Mouse basic 
kit (Vector Laboratories, Burlingame, CA) was utilized according to the manufacturer's 
instructions. Sections were incubated with primary antibody, Rabbit anti-GFP (1:250 Invitrogen 
A-6455), for each experiment, two tissue sections from the same animal were developed: one 
with primary antibody included and one with the primary antibody left out of the reaction. 
Visualization of GFP was done using the Vectastain Elite ABC kit (Vector Laboratories), used 
according to the manufacturer's instructions. All sections were developed using 3,3′-
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diaminobenzidine (Vector Laboratories) as the developing substrate and counterstained with 
haematoxylin. Images were taken at 20X magnification using a Nikon Eclipse Ti-S microscope 
with mmi Cell Tools software, Version 3.47. (MMI, Eching, Germany) For all images, treatment 
and control slides were sequentially imaged using the same exposure time and LUT settings. The 
slides were blindly quantified for the number of metastatic nodules on each section followed by 
the use of ImageJ software to determine the cross sectional area (µm
2
) of each nodule. The area 
was represented as an average size for each mouse and the total tumor burden was calculated by 
adding together the total cross sectional areas for all tumors in each mouse then averaged for 
each of the three groups.  
Statistics  
Statistical analysis was performed by ANOVA comparison between groups followed by 
Bonferonni posttest where * p> 0.05, ** P>0.01, *** P>0.001, and **** P>0.0001.  
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Results 
Three melanoma lines exhibit aggressive in vitro phenotypes, independent of Ras vs. BRAF 
mutation status 
 In our initial experiments, we analyzed the five human, metastatic melanoma cell lines 
using in vitro models of cancer aggressiveness. Using a clonogenicity assay, we find that SK-
Mel-147, SK-Mel-103 and UACC-257 readily formed colonies while SK-Mel-19 and SK-Mel-
29 were unable to form quantifiable colonies under these conditions (Fig. 4-1A). We next 
examined 2-dimensional and 3-dimensional cellular migration and invasion using the scratch-
wound migration assay (Fig. 4-1B) as well as a label-free transwell migration, (Fig. 4-2B) and 
Matrigel® invasion assay (Fig. 4-1C). Again we saw a consistent grouping of the cells where 
SK-Mel-147, SK-Mel-103 and UACC-257 showed a more aggressive phenotype. These three 
lines included two NRAS mutants and one BRAF mutant. To assess the role of proliferation per 
se in these functions, we measured growth over 4 days and found no consistent difference among 
the five cell lines under the low serum conditions used for all of these studies (Fig. 4-2A). Thus 
the BRAF/NRAS mutational status of the melanoma cell lines was not a predictor of the 
outcome in any of our in vitro models, however there is an obvious dichotomy in aggressive 
phenotypes between the two groups  
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Figure 4-1. Using cell-based models of metastasis the melanoma cells separate into 
aggressive and nonaggressive groups. 
A.) Clonogenicity was determined by seeding 200 live cells/well (determined by trypan blue 
exclusion) into 6-well plates. After 10 days the colonies were fixed and stained with crystal 
violet and the total number of colonies in each well was determined using >50 cells/colony cut 
off. Data are expressed as the mean (±STD) of duplicate experiments. B.) Cellular migration 
determined by wound assay. Cells are grown to confluence in 12-well plates then a scratch is 
made using a 200 µL pipette. Images are taken at 0 and 24 hours in 2.0% serum. Shown are 
examples of SK-Mel-19 and SK-Mel-147 after 24 hours; from experiments with similar initial 
wound areas. Quantification of the open area is determined computationally and the migration of 
each cell type relative to SK-Mel-19 after 24 hours is shown; Results are expressed as the mean 
(±SEM) of triplicate experiments (*** P< 0.001 vs. SK-Mel-19). C.) Real-time Analysis of 
Melanoma Cell Invasion. xCELLigence label-free system was used to monitor real-time 
Matrigel™ invasion of SK-Mel-147, UACC-257, SK-Mel-103, SK-Mel-19, and SK-Mel-29 in 
RPMI containing 0.5% FBS. Shown is a representative figure of the change in cell index 
(±SEM) from one experiment performed in triplicate. For each condition at least two 
independent experiments were performed.   
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Figure. 4-2. Melanoma cell line transwell migration and proliferation.   
A.) Proliferation is independent of clonogenicity, migration, and invasion in metastatic 
melanoma. Each cell line was grown in DMEM containing 2.0% FBS for 24 and 96 hours and 
proliferation was measured using the trypan blue exclusion assay. The aggressive melanomas, 
determined by clonogenicity, migration, and invasion assays are shown in black bars and the less 
aggressive melanomas are shown in white open bars. Results are expressed as the mean (±SEM) 
of triplicate experiments. B.) Real-time Analysis of Melanoma Cell migration. xCELLigence 
label-free system was used to monitor real-time transwell migration of SK-Mel-147, UACC-257, 
SK-Mel-103, SK-Mel-19, and SK-Mel-29 in RPMI containing 0.5% FBS. Open symbols 
indicate BRAF
V600E
 and filled symbols NRAS
Q61N
 mutants. Results are expressed as the mean 
(±SEM). 
103 
 
Aggressive melanomas selectively overexpress RhoC but not RhoA 
 Rho GTPase signaling has been shown to promote cellular migration and invasion (25). 
More specifically in melanoma, RhoC expression was increased in cell lines selected in mice for 
increased metastatic behavior (5). To determine the relative Rho signaling potential within our 
panel of melanomas we quantified RhoA and RhoC protein expression. When compared to 
GAPDH, RhoC protein is overexpressed in the aggressive melanomas; UACC-257, SK-Mel-147, 
and SK-Mel-103 (Fig. 4-3). Interestingly, RhoA levels are not significantly different within this 
panel of melanoma cell lines. RhoA plays an important role in proliferation and cytokinesis 
whereas RhoC seems to be more involved in migration, invasion, and metastasis (3,4)   
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Figure. 4-3. Aggressive melanomas selectively overexpress RhoC but not RhoA.  
A.) Western blot analysis of RhoA, RhoC, and GAPDH. Each melanoma cell line was starved 
for 24 hours in 0.5% serum prior to preparation of total protein lysates. Image is representative 
blot from three separate experiments. B,C.) Quantitative band density analysis was performed for 
each experiment comparing the intensity of RhoA and RhoC relative to the normalizing protein 
GAPDH. Results are expressed as the mean (±SEM) of triplicate experiments (** P< 0.01 vs. 
SK-Mel-19). 
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RhoC overexpressing, aggressive melanoma lines maintain spontaneously nuclear and active 
MRTF-A through F-actin stress fiber formation 
 MRTF localization and activity are regulated by G-actin. Stress fiber formation leads to 
G-actin depletion and MRTF translocation into the nucleus (9). UACC-257, SK-Mel-103, and 
SK-Mel-147 (shown) express strong F-actin staining and stress fiber formation in the absence of 
serum stimulation (Fig. 4-4A). By comparison SK-Mel-19 (shown) and SK-Mel-29 show 
reduced F-actin staining and very little stress fiber formation. Consistent with the actin-based 
mechanism governing MRTF localization and activity, the aggressive melanomas also exhibited 
spontaneously nuclear MRTF-A under these conditions (Fig. 4-4A). To show that MRTF-A 
localization was dependent on F-actin dynamics, we stimulated SK-Mel-19 with 20% FBS to 
induce stress fiber formation which induced MRTF-A nuclear localization (Fig. 4-5). We also 
treated SK-Mel-147 with latrunculin B which inhibits F-actin formation (26) and MRTF-A 
relocated to the cytosol (Fig. 4-5). Along with localization, MRTF activity is regulated by the 
relative levels of G-actin (27). To measure MRTF activity we determined the mRNA expression 
of three known Rho/MRTF target genes, myosin regulatory light chain 9 (MYL9), cysteine-rich 
angiogenic inducer 61 (CYR61), and connective tissue growth factor (CTGF). Consistent with 
the predominantly nuclear MRTF-A, the three aggressive lines (UACC-257, SK-Mel-147, and 
SK-Mel-103) have dramatically increased expression of these three Rho/MRTF-regulated genes 
compared to that in the other two lines (Fig. 4-4B). Along with being MRTF target genes, 
MYL9, CYR61, and CTGF play important roles in cellular migration and metastasis (11,28,29). 
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Figure. 4-4. MRTF-A localization and activity is increased with F-actin stress fiber 
formation in aggressive melanoma cells.   
A.) Cellular localization of MRTF-A observed with immunocytochemistry in starved (0.5% 
FBS, 24 hours) melanoma cells.  Images were quantified by scoring an individual cell as 
predominantly nuclear, cytosolic, or even distribution of MRTF-A. F-actin staining was also 
performed in the same cells using fluorophore-conjugated phalloidin toxin. Counts are from 
three independent experiments with at least 100 cells scored for each condition. For stress fiber 
quantification, only cells expressing prominent stress fiber bundles were determined to be “stress 
fiber positive”. Results are expressed as the mean (±SEM) of triplicate experiments (* P< 0.05, 
** P< 0.01 vs. SK-Mel-19) Scale bar shown represents 200µm B.) Expression of MRTF-A target 
genes known to be regulated by Rho/MRTF activity and involved in cancer migration; myosin 
regulatory light polypeptide (MYL9), cysteine-rich angiogenic inducer 61(CYR61), and 
connective tissue growth factor (CTGF), are quantified by qPCR. Results are expressed as the 
mean (±SEM) of triplicate experiments. 
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Figure. 4-5. Regulation of MRTF-A localization in serum-starved melanomas is determined 
by actin dynamics. 
Cellular localization of MRTF-A is observed with immunocytochemistry. Top, SK-Mel-19 cells, 
which exhibit almost exclusively cytosolic MRTF-A in the absence of serum were starved for 
23.5 hours in 0.5% FBS DMEM and then stimulated with 20% FBS for 30 minutes before 
fixation and staining for MRTF-A and F-actin. Bottom, SK-Mel-147 cells, which exhibit nuclear 
MRTF-A under starved conditions were starved for 23.5 hours in 0.5% FBS DMEM and then 
treated with 300nM latrunculin B for 30 minutes before fixation and staining for MKL1 and F-
actin. Latrunculin B is a natural toxin which blocks F-actin formation. Scale bar shown 
represents 200µm. Shown are representative examples from triplicate experiments. 
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MRTF pathway inhibitor CCG-203971 blocks MRTF-A nuclear accumulation and transcription 
activity  
 We next wanted to assess the potential for using a novel small-molecule inhibitor of the 
Rho/MRTF pathway to block in vitro and in vivo models of melanoma metastasis. In order to 
assess transcriptional activity of MRTF, we performed luciferase assays with a modified serum 
response element promoter (SRE.L) that is selective for MRTF (12). CCG-203971 inhibits 
RhoC-induced SRE-Luciferase expression in SK-Mel-147 cells with an IC50 of ~6 µM. 
Importantly, CCG-203971 does not cause cellular toxicity up to 100 µM using the WST-1 
viability assay (Fig. 4-6A). As previously reported by others (30) for compounds in this series, 
CCG-203971 reduces the nuclear localization of MRTF-A in SK-Mel-147 cells in a 
concentration dependent manner (Fig. 4-6B). CCG-203971 also reduces the expression of 
endogenous MYL9, CYR61, and CTGF in SK-Mel-147 cells (Fig. 4-6C) at low µM 
concentrations. 
 
CCG-203971 inhibits cellular migration and invasion  
 To determine if inhibition of MRTF localization and activity altered phenotypes of the 
aggressive melanoma lines, we investigated the influence of CCG-203971 at the cellular level. 
Using transwell migration and label-free Matrigel invasion assays we found that 10 µM CCG-
203971 inhibited cellular migration (Fig. 4-7A) and invasion (Fig. 4-7B) of the aggressive, RhoC 
overexpressing melanoma SK-Mel-147. Equally interesting, CCG-203971 has no effect on SK-
Mel-19, which does not display nuclear MRTF-A under these conditions (Fig. 4-4A). 
109 
 
 
Figure. 4-6. CCG-203971 regulates cellular localization and blocks MRTF target gene 
expression. 
A.) SK-Mel-147 cells were cotransfected with RhoC expression plasmid along with SRE.L 
reporter plasmid as described in Materials and Methods. Cells were treated with the indicated 
concentrations of CCG-203971 overnight after transfection before lysis and reading 
luminescence in the plate reader. Data are graphed as a percentage of the DMSO-negative 
control. B.) Immunocytochemistry was performed along with the indicated concentrations of 
CCG-203971 on SK-Mel-147 cells which under starved conditions (0.5% FBS, 24 hours) 
maintained nuclear MRTF-A. As described previously, individual cells were determined to 
express predominately nuclear, cytosolic, or even distribution of MRTF-A. Data are the averages 
of three independent experiments with at least 100 cells counted for each condition. Scale bar 
shown represents 200µm. C.) CCG-203971 effect on gene expression of CTGF, MYL9, and 
CYR61. SK-Mel-147 cells were starved in 0.5% media for 24 hours in the presence of   the 
indicated concentration of CCG-203971 or DMSO before isolation of RNA for qPCR analysis. 
Results are expressed as the mean (±SEM) of triplicate experiments (* P< 0.05, ** P< 0.01 vs. 
DMSO control). 
110 
 
 
Figure. 4-7. CCG-203971 inhibits cellular migration and invasion.  
A.) CCG-203971 blocks melanoma migration. Cells were seeded into the top of a transwell 
migration chamber with 0.5% on top and bottom to measure basal migration of SK-Mel-19 and 
SK-Mel-147. CCG-203971 (10µM) blocked SK-Mel-147 migration. Shown on the left are 
images at 4X magnification using a bright field microscope after six hours of migration. On the 
right four random fields of view at 20X magnification are quantified for the number of cells 
which migrated through the membrane. Results are expressed as the mean (±SEM) of triplicate 
experiments. B.) CCG-203971 inhibits invasion in aggressive melanoma. Real-time Analysis of 
cellular invasion was analyzed using the xCELLigence label-free system. SK-Mel-147 and SK-
Mel-19 were each treated with 10μM CCG-203971 or DMSO control and allowed to invade 
through Matrigel™ in RPMI containing 0.5% FBS. Shown is a representative figure of the 
change in cell index (±SEM) from one experiment performed in triplicate. For each condition at 
least two independent experiments were performed. 
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CCG-203971 blocks melanoma lung metastasis 
 There are very few clinically available, effective therapeutics for metastatic melanoma. 
To determine the potential for MRTF pathway inhibitors as metastasis-targeting therapeutics, we 
treated mice with CCG-203971 (100 mg/kg BID) or vehicle control for 18 days following tail 
vein injection of GFP-expressing SK-Mel-147 cells. To compare the in vivo effects to the 
cellular phenotypes we observed in the in vitro assays, we also injected mice with GFP-
expressing SK-Mel-19 cells. The RhoC overexpressing SK-Mel-147 cells readily formed lung 
metastases following I.V. injection (Fig. 4-8A). The SK-Mel-147 injected mice not only 
displayed more metastatic nodules (~3X) but the tumors were much larger (~5X greater area) 
than the SK-Mel-19 injected mice (Fig. 4-8B). This difference was compounded when 
considering the total tumor burden (~15X more). The CCG-203971 treated group contained 
about half as many tumors which were also about 1/4 the size. This resulted in a final tumor 
burden around 7X lower than in the vehicle treated group (Fig. 4-8B). 
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Figure. 4-8. Rho/MRTF pathway effect on experimental lung metastasis 
Immunocompromised mice were separated into three groups. One group received tail vein 
injection of GFP expressing SK-Mel-19 (2X10
6
 cells). The other two groups were injected with 
GFP expressing SK-Mel-147 (2X10
6
 cells). Following tail vein injection the mice began twice 
daily I.P. injection of 100mg/kg CCG-203971 or 50μL DMSO (vehicle control). After 18 days 
the mice were euthanized and lungs were collected for histological analysis. Sections from each 
lung were immunohistologically probed for GFP. Images were taken at 20X magnification, 
shown are two representative images of metastatic colonies from each group. Scale bar 
represents 400µm. Each slide was visually scanned for total number of lung colonies, and the 
average tumor area was determined using image analysis software. The total tumor burden was 
calculated by adding together the total cross-sectional area of all colonies identified within each 
mouse. Data is represented as the mean (±SEM) of n=6 (SK-Mel-19+DMSO and SK-Mel-
147+DMSO) and n=5 (SK-Mel-147+CCG-203971). (* P< 0.05, *** P< 0.001 vs. SK-Mel-
19+DMSO). (+ P< 0.05, +++ P< 0.001 vs. SK-Mel-147+DMSO). 
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Discussion  
 Mutations in BRAF and NRAS, leading to constitutive activation of the mitogen-
activated protein kinase (MAPK) pathway, are found in nearly ~60-70% of primary human 
cutaneous melanomas (31,32). However, these driver mutations do not appear to govern the 
propensity for metastasis; BRAF vs. NRAS mutation status does not predict patient overall 
survival (33-36). Consequently, it would be important to better understand factors that drive 
aggressiveness and metastasis of human melanomas. Based on the role of RhoC and MRTF-
regulated gene transcription in genetic studies in mouse B16F2 melanoma and breast cancer 
models (2, 4, 11), we wanted to explore the role of those mechanisms in human metastatic 
melanoma.  
 Among 5 human cell lines derived from metastatic cutaneous melanomas, two distinct 
biological phenotypes were observed. The three melanoma lines (UACC-257, SK-Mel-103, and 
SK-Mel-147) that behaved aggressively in vitro (clonogenicity, migration, invasion) showed 
strong over-expression of RhoC protein and activation of MRTF-regulated gene expression even 
in low serum conditions. Furthermore, Sk-Mel-147 which has high RhoC/MRTF activity 
exhibited numerous lung metastases after tail vein injection in immunocompromised 
(NOD/SCID) mice while SK-Mel-19, which had low RhoC/MRTF activity, did not. The 
RhoC/MRTF mechanism is relevant to the biological aggressiveness of the three lines since the 
phenotypes were reversed by the small molecule inhibitor (14) of MRTF-regulated gene 
transcription, CCG-203971.    
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 While mutations in Rho proteins are rare, review of cancer genomic information through 
cBioPortal, (37,38) showed that 31% of cutaneous melanomas had amplification or mutation of 
RhoA/C, MKL1/2 (gene names for MRTFA/B) or upstream activators (GNA12, GNA13, 
GNAQ, GNA11 or ARHGEF11). Furthermore, an outlier analysis of melanoma in Oncomine, 
(39) showed that 5-20% of melanomas across several studies had marked up-regulation of RhoC 
at the transcriptional level. Mechanisms driving this are not known but could include regulation 
by the ETS-1 transcription factor (40,41). Loss of E-cadherin in melanoma leads to ETS-1 
activation and enhanced RhoC expression (40). RhoC induces c-Jun expression (likely through 
MRTF/SRF mechanisms) which contributes to cell survival (40). This could partially explain the 
increased clonogenicity observed in the three RhoC overexpressing melanomas as well as the 
increased lung colonization by SK-Mel-147.  
 In light of the multiple genes and pathways that can lead to activation of Rho and MRTF-
regulated transcription, inhibition at a downstream step in the pathway would be essential to 
disrupt the plethora of potential activation mechanisms (42,43). Our compound, CCG-203971 
prevents the nuclear accumulation of MRTF potentially by directly binding to MRTF (19)  or by 
modulating intranuclear actin regulation by MICAL2 (20). Previous work has already provided 
genetic validation of this approach as a means of suppressing metastasis for both melanoma and 
breast cancer (11). Here we demonstrate the potential for an anti-metastatic small molecule 
therapeutic that targets this gene transcription mechanism by showing marked suppression of 
SK-Mel-147 lung metastasis with in vivo treatment with CCG-203971. While it has been argued 
that antimetastatic therapies are not useful or are difficult to test clinically, there is increasing 
recognition that this approach has value (44). Continued efforts to optimize MRTF-transcription 
inhibitors like CCG-203971 will be needed. In particular enhancing potency with reduction of 
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acute toxicity (13,14) is required for chronic treatments that would be required for anti-
metastasis therapies. Furthermore, improved bioavailability and pharmacokinetics would 
facilitate both preclinical and potentially clinical studies. 
 In addition to melanoma, spontaneous nuclear localization of MRTF-A has been reported 
in MDA-MB-231 breast cancer cells (11). The MDA-MB-231 cells are often used as a model of 
aggressive breast cancer cells. Intriguingly they also harbor a Ras mutation (KRAS) (45). Of the 
three melanomas with enhanced RhoC expression and spontaneous MRTF-A nuclear 
localization, two had NRAS mutations. Since latrunculin was able to redistribute MRTF into the 
cytoplasm it appears that there is not a change in the transcription factor itself but in the actin 
mechanisms (potentially upstream RhoC signaling) that govern its localization.  
 Rho GTPases and their downstream pathways have also been recognized as drug targets 
for several years. Virtual screening approaches recently led to the development of small-
molecules which inhibit the interaction between RhoA and its GEFs (46,47). These compounds 
produce in vitro efficacy but have not shown effects in vivo, potentially due to limited potency 
and pharmacokinetic issues. Another common approach is to target the Rho kinase (ROCK). 
ROCK inhibitors block cellular invasion of melanoma cells and reduce tumor volume in vivo 
(48). However their maximal capacity for inhibition of the MRTF transcription mechanism is 
less than that of CCG-203971 (12), perhaps in part due to parallel pathways and homologous 
kinases that can activate MRTF/SRF (12,14). So targeting at the MRTF level may be a more 
effective approach.  
 Thus Rho-regulated, MRTF-mediated gene transcription signaling appears to play an 
important role in migration, invasion, and metastasis of human cutaneous melanoma. Expression 
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levels of RhoC and MRTF target genes may provide useful biomarkers to identify cancers with 
propensity for metastasis as well as for targeted therapies by this approach. Small molecule 
inhibitors of this pathway, such as enhanced CCG-203971 analogs, represent an exciting class of 
pharmacological probes and potential future therapeutics.  
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 Scleroderma and metastatic melanoma remain debilitating and deadly diseases (1,2). 
Previous evidence suggests the Rho small GTPase modulation of gene expression through the 
MRTF/SRF transcription pathway plays a significant role in the initiation, stabilization, and 
progression of these diseases (3-7). The goal of my research was to understand the signaling 
mechanisms where by Rho activation leads to MRTF/SRF regulated transcription in these 
diseases, and to determine efficacy of small-molecule inhibitors of this pathway in pre-clinical 
models of scleroderma and melanoma. An overall goal of my work is to promote the 
development of targeted therapeutics, which blocks the Rho/MRTF pathway to treat these 
aggressive diseases.  
 In Chapter II, I focused on understanding how TGFβ ligand stimulation leads to 
activation of Rho/MRTF regulated transcription. One of the major challenges in developing 
targeted therapeutics for scleroderma and other fibrotic diseases is the multitude of receptor 
signaling mechanisms which appear to play a role in these diseases (8,9). This is supported by 
multiple clinical trials for IPF and scleroderma which have been terminated early due to lack of 
efficacy (8). Based on our results in Chapter II, TGFβ and Rho GTPase participate in a variety of 
cross-talk mechanisms. To further complicate resolving these pathways, it has recently been 
shown that TGFβ stimulates nuclear accumulation of MRTF where it forms a transcriptional 
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complex with SMAD3 (10). This adds a new level of complexity to our model of the mechanism 
whereby TGFβ activates MRTF. MRTF nuclear localization in the context of TGFβ is dependent 
on Rho activation as we hypothosize and is supported in Chapter II, (10), however, our 
experiments did not investigate the nuclear complex partners (SRF or SMAD3) which interacted 
with MRTF after TGFβ or LPA ligand stimulation. Co-immunoprecipitation experiments with 
MRTF, SRF, and SMAD3 following early and late TGFβ treatment could provide some 
interesting insight around these questions.   
 As shown in Chapter II, the ROCK inhibitor clearly supported categorizing specific 
profibrotic genes as being SMAD or MRTF targets, however, in this same experiment, treatment 
with CCG-203971 in Chapter III, non-selectively blocked stimulated expression of all profibrotic 
genes. One major difference in these compounds is where in the pathway they inhibit MRTF-
regulated transcription. ROCK stimulates actin stress fibers through phosphorylation of multiple 
downstream targets leading to F-actin formation and stabilization (11). Inhibition of ROCK leads 
to decreased stress fibers and MRTF nuclear accumulation and activity. Interestingly we have 
previously found ROCK inhibitors to only have partial efficacy for the inhibition of MRTF, 
depending on where the pathway is stimulated (12),(13). CCG-203971 and related compounds 
however target downstream of F-actin formations and have been shown to bind and inhibit a 
nuclear actin modifier protein MICAL2 (14) and also MRTF itself (15). Through either 
mechanism, compounds from this series have been shown to block nuclear accumulation of 
MRTF. Although there are many potential reasons for these differences observed between these 
compounds, the step in the pathway where they inhibit could play a significant role. There is 
obvious cross-talk between TGFβ/SMAD and Rho/MRTF (10), by blocking upstream of MRTF 
using a ROCK inhibitor could allow for expression of SMAD target genes independent of 
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MRTF, however by blocking very downstream in the pathway using CCG-203971 SMAD target 
genes may have become MRTF dependent leading to the inhibition we observed in this assay. 
Further understanding the molecular target of CCG-203971 and related compounds could 
support, or oppose this hypothesis. 
 We also found that TGFβ target genes EDN1 (Endothelin) and CTGF are able to 
stimulate Rho/MRTF when added exogenously to fibroblasts, and inhibition of these mediators 
with an endothelin receptor type A antagonist and a CTGF neutralizing antibody is able to block 
TGFβ induced activation of actin stress fibers and activity of MRTF. This outlines a mechanism 
where TGFβ stimulates rapid expression of endothelin and CTGF which then autocrine signal 
back onto the cells to stimulate Rho GTPase and expression of pro-fibrotic genes through 
MRTF. This model mostly focuses on the signaling pathways after TGFβ, however, equally 
interesting was the role of LPA in the subtle activation (~20%) of MRTF/SRF activity observed 
in the absense of serum or TGFβ. To add to this, we found that TGFβ treatment caused a rapid 
reduction in the expression of the gene encoding autotaxin, the enzyme which synthesizes LPA. 
This leads to a hypothesis where TGFβ potentially shifts MRTF/SRF activity from being driven 
by LPA to one driven by CTGF and ET-1. This could further be supported by determining the 
level of released LPA into the medium of TGFβ stimulated cells. Another intesting experiment 
would be analyzing the profibrotic, MRTF and SMAD target genes following LPA, CTGF, and 
ET-1 treatment to determine if there is specificity between these ligands or if they just combine 
for  additive activation.   
 In Chapter III, we shifted focus onto the small-molecule MRTF pathway inhibitors 
developed in our lab, in pre-clinical models of scleroderma. From a mechanistic perspective, the 
nonspecific inhibtion of profibrotic genes with CCG-203971 observed in Chapter III were not as 
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clean as what we obrserved with the ROCK inhibitor, they did suggest the potential for exciting 
efficacy against a fibrotic disease like scleroderma. Consistant with the idea that the Rho/MRTF 
pathway is activated in scleroderma patient fibroblasts vs. normal healthy donor fibroblasts, 
CTGF, ACTA2, and COL1A2 were all elevated in the scleroderma patient derived fibroblasts. In 
these patient samples CCG-203971 was able to block gene expression at low micromolar 
concentrations. We also tested the efficacy of pirfenidone to block expression of these genes in 
the scleroderma patient samples. At the time of this study  prifenidone was approved for the use 
of IPF in Asia, Europe, and Canada but still awaiting approval in the United States, however in 
October, 2014 pirfenidone (trade name Esbriet®) was approved for use against IPF by the US 
FDA. Similar to CCG-203971, pirfenidone does not have a known molecular target. It has been 
shown to redeuce production of inflammatory cytokines TNF-α and TGFβ (16,17). Pirfenidone 
may also block TGFβ induced transcription as it was found to inhibit nuclear localization of 
SMADs (18). Importantly it should be noted that pirfenidone is used at extremely high doses and 
concentrations, similar to the 300µM in vitro concentrations used in our experiments. We also 
performed a simple cellular proliferation experiment comparing these cells. We found 
scleroderma patient samples displayed slightly elevated growth rates compared to the normal 
donor samples. Most interestingly high cencentation treatment (30µM) with CCG-203971 
selectively blocked the enhanced proliferation of the scleroderma cells while not affecting the 
normal samples. Transformed myofibroblasts are resistant to apoptosis (19,20) and designing 
therapies which can resensitize myofibroblasts to apoptosis is a current focus of novel 
therapeutics (21). The assay we performed here measured activity of cellular reductases and 
nondescriptively determines relative viable cells. Based off of the results here, CCG-203971 is 
reducing the total number of viable cells by selectively targeting the activated myofibroblast 
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cells for apoptosis, or by converting them back to more quiescent fibroblasts. Further analysis of 
the mechanism whereby CCG-203971 reduces the total number of viable cells is a crucial next 
step. Apoptosis assays measuring caspase activation or cell cycle analysis of scleroderma derived 
fibroblasts or TGFβ stimulates normal donor fibroblasts in the presenence of CCG-203971 could 
begin to answer these questions. In our next experiments we focused on α-SMA as a marker of a 
transformed myofibroblast. CCG-203971 was able to block α-SMA expression in TGFβ 
stimulated normal donor fibroblasts as well as, and most significantly, constituative α-SMA 
expression observed in unstimulated sclerderma patient derived fibroblasts. This was significant 
because blocking TGFβ stimulated transformation of healthy donor fibroblasts can be viewed as 
a “prevention” study, where as reversing scleroderma transformation, or enriching for a 
population of non-transformed cells can be viewed as a “treatment” study. This is especially 
signifiant because our in vivo study was a prevention protocol. There are multiple in vivo models 
of scleroderma, but the two main revolve around bleomycin induced injury or the genetic Tsk/+ 
(tight skin) mouse model (22). Although both models have their flaws, bleomycin depends 
heavily on inflammation, while Tsk/+ is independent of inflammation, both models to offer 
insight into potential efficacy of novel therapeutics. In our bleomycin prevention, study mice 
were treated with 100mg/kg CCG-203971 BID, I.P. for two weeks. At the end of the study skin 
samples were obtained for trichrome staining and hydroxyproline analysis. The CCG-203971 
treated group not only had significantly thinner dermal layers than the control, bleomycin group, 
their skin collagen content was also reduced. Efficacy of CCG-20371 against in vitro and in vivo 
models of scleroderma provided evidence that these compounds have potential for treating 
providing proof of concept to treat diseases where the Rho/MRTF pathway is implicated. These 
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results also push towards developing more potent, metabolically stable analogs of this 
compounds series, which will be discussed at the end of this chapter.  
 In Chapter IV, we investigated the role of Rho GTPases and MRTF transcription in 
metastatic melanoma, and again look at efficacy of CCG-203971 in this disease. In the past 
decade, evidence has highlighted the similarities and consistencies between profibrotic diseases 
and cancer.  Broadly, both diseases are marked with, and driven by abnormal genetic and 
epigenetic changes, irregular response to regulatory mechanisms, and activation of stimulatory 
signaling pathways (23). Genetically, IPF patient derived fibroblasts are scattered with mutations 
in multiple cancer-associated genes including p21Waf1/Cip1/Sdi1 and p53, with the latter 
observed with heterogeneous point mutations in 80% of  IPF samples tested (24,25). Many cell-
signaling pathways, which are activated in cancer, are also stimulated in fibrotic diseases. TGFβ 
signaling, which has been discussed throughout these studies, also plays important roles in tissue 
invasion in lung cancer, melanoma, and breast cancer (26). Significant to our work Rho/MRTF 
signaling also plays major importance to cancer metastasis. Despite recently approved targeted 
therapeutics, melanoma remains a very deadly disease (27). One of the major problems in 
melanoma cellular biology is understanding the mechanisms and markers which will drive an 
aggressive, metastatic disease. Although exclusive mutations in BRAF and NRAS combine to be 
present in over 75% of tested human melanomas they do not predict a clinical prognosis (28). 
We found, within out panel of five melanomas, the invasive and metastatic cells displayed 
constitutive nuclear localization of MRTF-A. A very translational next experiment would be to 
investigate the localization of MRTF-A in a panel of melanoma patient samples and correlate 
prognosis, potential for metastasis, response to therapeutics, and survival.  
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 In our experiments with melanoma we also found the cells which overexpressed RhoC 
and displayed nuclear localization of MRTF-A also expressed high levels of CYR61 and CTGF  
(the genes which encode proteins CCN1 and CCN2). These matricellular proteins can signal 
through multiple mechanisms to regulate cell adhesion, migration, proliferation, differentiation, 
and apoptosis (29). Although plenty of evidence exists for the role of CTGF in cancer 
progression and tissue fibrosis, CYR61 has mostly been discussed in cancer metastasis for its 
ability to stimulate angiogenesis (30,31). There is evidence however, for a role of CYR61 in 
fibrosis, during the process of wound healing CYR61 regulates matrix deposition and survival of 
myofibroblasts (32). Based on what were learned from the melanoma experiments about CYR61 
being regulated by MRTF and CCG-203971, it would be important to identify its role in our 
fibrosis experiments  
 To move into an in vivo model of melanoma metastasis, we injected melanoma cells into 
the tail-vein of immunocompromised mice. CCG-203971 reduced the total number of lung 
colonies at the end of this experiment, as well as the cross sectional area of the colonies. This 
combined for a very dramatic reduction in the calculated total tumor burden. Within a tumor 
mass, malignant cancer cells are minority. The bulk of a tumor is made up of nonmalignant cells, 
mesenchymal cells, immune cells, vasculature, and extracellular matrix components (33-36). 
One of the major contributors to tumor biology are localized fibroblasts which can stimulate 
collagen production, stabilizing the tumor microenvironment, or also involved in invasion and 
metastasis where transformed fibroblasts are found at the leading end of invading melanomas 
(37). Evidence suggests malignant cancer cells release TGFβ onto the local fibroblasts, activating 
them into myofibroblasts which can then assist in survival, invasion, migration, proliferation, and 
ECM synthesis (38). In Chapter II and Chapter III we showed that TGFβ feeds into the Rho 
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GTPase/MRTF transcriptional pathway, and that CCG-203971 is able to block these mechanisms 
in immortalized mouse fibroblasts, and human dermal fibroblasts. We also however showed in 
Chapter IV that CCG-203971 blocks melanoma cellular migration and invasion, independent of 
fibroblast involvement. In our in vivo metastasis study CCG-203971 was given systemically, so 
lung fibroblasts and the injected melanoma cells were treated. Based on these experiments, and 
prior evidence, this suggests that the efficacy of CCG-203971 in our metastasis study could be a 
result of the compound effecting the cancer cells themselves, and also the compound blocking 
the involvement of local fibroblasts in aiding lung colonization. One very clear experiment to 
begin answering these questions would be to perform tri-chrome staining on the lung sections 
from our mouse metastasis study and determine if CCG-203971 reduced the amount of fibrotic 
tissue within, and surrounding the melanoma metastatic colonies.  
 Some of the major drawbacks of our current lead compound, CCG-203971 are the 
potency (5-10µM), the solubility, and the rapid metabolism/clearance of this compound. Using in 
silico prediction models of P450 metabolism (SMARTCyp) multiple metabolic sites on CCG-
203971 were predicted (Fig. 5-2A). Based off these results, multiple new analogs of CCG-
203971 were synthesized with the goal of increasing compound half-life. One of these analogs, 
CCG-222740, a 5, 5-difluoropiperidine substitution into CCG-203971 actually ended up being 
dramatically more potent than CCG-203971 (~600nM vs. ~8uM) in the MRTF dependent SRE-
Luciferase assay and is currently being tested in in vivo disease models and metabolic stability 
studies.  
 In these studies, we have identified mechanisms for MRTF activation in both fibroblasts 
and metastatic melanoma. TGFβ stimulated ET-1 and CTGF activate F-actin stress fibers and 
MRTF in fibroblasts, and RhoC overexpression leads to constitutively nuclear, active MRTF in 
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metastatic melanoma. We have also shown efficacy for our current lead small molecule inhibitor 
of this pathway, CCG-203971, in in vitro and in vivo models of tissue fibrosis and metastatic 
melanoma. Interestingly, throughout the timeline of my thesis work both of these diseases have 
had exciting therapeutic developments; Vemurafenib for the treatment of BRAF mutant 
metastatic melanoma, and very recently, pirfenidone for the treatment of IPF. Although both of 
these therapies leave much work to be done, they do represent a very dynamic time to study 
these diseases. Combined this work promotes further understanding pathological signaling 
mechanisms which stimulate MRTF/SRF gene transcription, and additional work into the 
development of novel therapeutics which target this pathway. 
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